untitled h1
untitled h2

Phase II Trial of VELCADE® (Bortezomib) in Combination with Temozolomide and Regional Radiation Therapy for Upfront Treatment of Patients with Newly-diagnosed Glioblastoma Multiforme.  
Protocol Version: Date of Protocol:
Original January 22, 2009 Amendment 1 February 14, 2011 Amendment 2 May 31, 2012 Amendment 3 August 1, 2012 Amendment 4 January 09, 2013 Amendment 5 March 13, 2013 Amendment 6 November 19, 2013 Amendment 7 February 11, 2014 Principal Investigator Dr. Albert Lai University of California at Los Angeles
untitled h1
study protocol

Protocol Number X05303 Phase II Trial of VELCADE® **(Bortezomib) in Combination with**
Temozolomide and Regional Radiation Therapy for Upfront Treatment of Patients with Newly-diagnosed Glioblastoma Multiforme.  
Protocol Version: Date of Protocol:  
Original January 22, 2009  
Amendment 1 February 14, 2011 Amendment 2 May 31, 2012 Amendment 3 August 1, 2012 Amendment 4 January 09, 2013 Amendment 5 March 13, 2013 Amendment 6 November 19, 2013  
Amendment 7 February 11, 2014  
  
Investigator &Study Center:
*VELCADE is the exclusive trademark of Millennium Pharmaceuticals, Inc., registered in the United States and internationally.
untitled h1
protocol summary title

Phase II Trial of VELCADE* (Bortezomib) in Combination with Temozolomide and Regional Radiation Therapy for Upfront Treatment of Patients with Newly-diagnosed Glioblastoma Multiforme.
untitled h1
objectives

This phase II study will examine the safety and efficacy of bortezomib in combination with temozolomide/radiation followed by bortezomib and temozolomide for 2 years (24 28-day cycles) in newly-diagnosed patients with glioblastoma. The primary objective of the study is to:  
Estimate the overall survival in subjects with newly-diagnosed glioblastoma
(GBM) treated with bortezomib/temozolomide/radiation followed by bortezomib/temozolomide for 24 cycles until progression is detected or for up to 24 cycles (~2 years).
The secondary objectives of this study are to:  
Investigate further the safety and tolerability of bortezomib/temozolomide/radiation followed by bortezomib/temozolomide.  
Collect frozen and paraffin patient tumor tissue to be utilized for MGMT
promoter methylation and IDH1 genotyping and for correlative molecular characterization to be submitted as a separate research study. Tissue must be obtained in all study patients from original surgery, and in those patients who will be undergoing resection at time of treatment failure and during the follow-up period.
untitled h1
patient population

This study will be open to newly-diagnosed patients with GBM that have not received other therapy other than surgery. Additionally, a key enrollment inclusion criterion is the collection of frozen tissue along with paraffinized tissue. This is necessary for MGMT promoter methylation and IDH1 genotyping studies and correlative molecular characterization. Specific inclusion and exclusion criteria are detailed in section 3.2.
untitled h1
study design and methodology

This will be a multi-center, open-label, phase II study assessing safety and efficacy in which adult newly-diagnosed GBM patients that have had no prior therapy, other than surgery, will receive bortezomib, temozolomide, and radiation all starting on day 1 (+/- 2 days) of study. Day 1 of the study must be no sooner than 2 weeks from surgery and no longer than 6 weeks after surgery, followed by bortezomib and temozolomide after completion of fractionated radiation for up to 24 additional cycles if no tumor growth is seen. At this point, both bortezomib and temozolomide will be discontinued, and the patient will be monitored with routine MRI surveillance until progression. There has recently been publication of a phase I
study that found no significant toxicities when bortezomib at a dose of 1.3 mg/ m2 (days 1, 4, 8, 11, 22, 25, 29, and 32) was combined with brain radiation and temozolomide for patients with newly-diagnosed or recurrent gliomas (Kubicek, Werner-Wasik et al. 2008). Of note, in the recurrent cases, patients had received prior radiation. Based on those findings, we will utilize the same bortezomib dosing used in that protocol, although the schedule will be slightly altered.  
Patients will receive 1.3 mg/m2 bortezomib subcutaneous on days 1, 4, 8, 11, 29, 32, 36, and 39 and temozolomide 75 mg/m2 daily during radiation. Bortezomib will be administered beginning on the first day of radiation with temozolomide. External beam fractionated regional radiation will be given on consecutive week days at 200 cGy daily doses to a total dose of 6000 cGy. After a 2-6 week rest (for temozolomide and bortezomib) following completion of radiation therapy, a maintenance phase (post-RT) of temozolomide will be restarted at 150 mg/ m2/day for 5 days out of every 28. (If this is tolerated, subsequent cycles will be given at 200 mg/ m2/day). Also, bortezomib at 1.3 mg/m² will be given on days 1, 4, 8, and 11 of a 28 day cycle commencing on the first day of temozolomide. Temozolomide will not be increased greater than 200 mg/m2/day. No increases in bortezomib above 1.3 mg/m² will be made. Treatment with bortezomib and temozolomide will continue for 24 additional 28 day cycles from radiation therapy if there is no evidence of progression. At that time, both bortezomib and temozolomide will be stopped if there is no evidence of disease progression. Note: If unacceptable toxicities after the first 12 cycles are observed, per investigator's discretion, the bortezomib dosing schedule may be changed to 1.3 mg/m2 weekly for 3 weeks on and 1 week off, with the possibility of further reduction if necessary to 1.3 mg/m2 biweekly.
untitled h1
efficacy data collected

The following evaluations will be conducted to assess the efficacy of the combination of bortezomib, temozolomide and radiation:  
Overall survival Time to progression Progression free survival Radiographic response (when evaluable)
VELCADE (bortezomib) for Injection UCLA Neuro-Oncology Program Pharmacokinetic/Pharmacodynamic/Pharmacogenomic/Correlative studies:
the content of the conte  
  
Safety data collected:
The following evaluations will be conducted to assess the safety of VELCADE:
Toxicity/safety: Patients will be assessed using CTC 3.0.  
.
untitled h1
statistical procedures

The sample size calculation for this one-arm trial is based on an endpoint of an 18-month s survival rate with a 36-month accrual period (1-2 patients/month).  
The following assumptions are made:  1. Survival time follows an exponential distribution, 2.  
The 18month survival rate is 55% (median survival 21 months) for the new treatment and 40% (median survival 14 months) for the standard treatment (based on (Stupp, Mason et al. 2005), 3. The 18-month survival rate is estimated using the Kaplan-Meier method, 4. Test statistics
- Z-test, Type I error=0.05, 5. N=50 (total patients). In a performed simulation, the power is 70% for 1-sided test. After 10 patients with newly-diagnosed GBM are treated, an interim analysis will be conducted. If 3 or more patients have experienced unacceptable toxicity (defined as a grade 4 non-hematologic toxicity or any grade 5 toxicity), enrollment will be suspended pending full assessment of safety risks to determine if the study should continue. Otherwise, patient accrual will continue. The primary endpoint will be total survival from the date of surgical-pathological diagnosis. For the final analysis, endpoint results will be compared with the results on comparable patients whose data are available through the UCLA Neuro-Oncology Department database. These comparable patients were all newly diagnosed GBM patients who were treated on research protocols and similar to the patients in the present study insofar as were seen at a tertiary center and enrolled into clinical trials early after diagnosis. The primary analysis will utilize a Cox proportional hazards model including age, KPS, and extent of resection. This allows for adjustment for major prognostic factors.  
| TABLE OF CONTENTS   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 1                   | INTRODUCTION AND STUDY RATIONALE 11 1.1 Overview of the Disease 11 1.2 VELCADE (bortezomib) for Injection 12 1.2.1 Scientific Background 12 1.2.2 Nonclinical Pharmacology 13 1.2.3 Nonclinical Toxicity 14 1.2.4 Clinical Pharmacokinetics and Pharmacodynamics 14 1.2.5 Clinical Experience 16 1.2.6 Potential Risks of Bortezomib 20 1.2.7 Precautions and Restrictions 26 1.3 Temozolomide (see product insert) 27 1.3.1 Scientific Background 27 1.3.2 Nonclinical Pharmacology 27 1.3.3 Nonclinical Toxicity 27 1.3.4 Clinical Pharmacokinetics and Pharmacodynamics 27 1.3.5 Clinical Experience 27 1.3.6 Potential Risks of Temozolomide 27 1.4 Study rationale and selection of drug doses 27                                                                                                                                                                                                                                                                                                     |
| 2                   | STUDY OBJECTIVES 30 2.1 Primary Objective 30 2.2 Secondary Objectives 30                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| 3                   | INVESTIGATIONAL PLAN 31 3.1 Overall Design and Plan of the Study 31 33 3.2 Selection of Patients 36 3.2.1 Inclusion Criteria 36 3.2.2 Exclusion Criteria 38 3.3 Study Treatments 39 3.3.1 Clinical Trial Materials 39 3.3.2 Preparation, Handling, and Storage of Drugs 40 3.3.3 Dose Modification and Delay 43 3.3.4 Treatment Assignment 48 3.3.5 Blinding, Packaging, and Labeling 48 3.3.6 Concomitant Treatment 48 3.3.7 Treatment Compliance 49 3.4 Duration of Treatment and Patient Participation 49 3.5 Termination of Treatment and/or Study Participation 49 3.6 Efficacy, Pharmacodynamic/Pharmacogenomic/Correlative studies, and  Safety Measurements 50 3.6.1 Efficacy Measurements 50 3.6.2 Pharmacokinetic/Pharmacodynamic/Pharmacogenomic/Correlative  Studies 51 3.6.3 Safety Measurements 52 4.1 Definitions 52 4.1.1 Adverse Event Definition 52 For this protocol an abnormal laboratory value will not be assessed as an  AE unless that value leads to discontinuation or delay in |  
| VELCADE (bortezomib) for Injection  UCLA Neuro-Oncology Program  treatment, dose modification, therapeutic intervention, or is  considered by the investigator to be a clinically significant  change from baseline 53 4.1.2 Serious Adverse Event Definition 53 4.2 Procedures for AE and SAE Reporting 53 4.3 Procedures for Reporting Drug Exposure during Pregnancy and Birth  Events 55 5 STATISTICAL PROCEDURES 56 5.1 Sample Size Estimation 56 5.2 Randomization and Stratification 56 5.3 Populations for Analysis 56 5.4 Procedures for Handling Missing, Unused, and Spurious Data 56 5.5.1 Baseline Comparisons 56 5.5.2 Efficacy Analysis 56 5.5.3 Safety Analysis 58 5.6 Interim Analysis 62 5.7 Procedures for Reporting Deviations to Original Statistical Analysis Plan 62 6 ADMINISTRATIVE REQUIREMENTS 63 6.1 Product Complaints 63 7 REFERENCES 64 VELCADE REFERENCES 66 8 APPENDICES 70 8.1 Study Flow Chart 70 8.2 Karnofsky Performance Status Scale (The following table presents the  Karnofsky performance status scale ) 71 8.3 Body Surface Area and Creatinine Clearance Calculations 72 8.4 New York Heart Association Classification of Cardiac Disease 73 8.5 Declaration of Helsinki 74 8.6 Common Terminology Criteria for Adverse Events Version 3.0 78 8.7 RTOG/EORTC Late Radiation Morbidity Scoring Scheme 78 8.8 FACT/GOG-Neurotoxicity Questionnaire, Version 4.0 81 8.9 Sample Collection and Handling Requirements; 20S Proteasome  Inhibition Assay 81 8.10 Sample Collection and Handling Requirements; PK 81 8.11 Sample Collection and Handling Requirements; PGx 81 8.12 RADIATION THERAPY GUIDELINES 81 8.13 Drugs known to be metabolized by CYP450 isoenzyme 3A4 84   |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|  
List of Tables and Figures in the Text Tables Table 3-1 Management of Patients with VELCADE Related Neuropathic Pain and/or Peripheral Sensory or Motor Neuropathy ................................................. 39  
| VELCADE (bortezomib) for Injection  UCLA Neuro-Oncology Program  Abbreviations List  Abbreviation Definition C degrees Celsius M Micromolar 20S 20S proteasome subunit AE adverse event ANC absolute neutrophil count Bc1-2 B-cell lymphoma-2; a gene that inhibits apoptosis BSA body surface area CAM cell adhesion molecules  Cm Centimeter CR Complete Response CTCAE (NCI) Common Terminology Criteria for Adverse Events CTEP Cancer Therapy Evaluation Program dL Deciliter DLT Dose Limiting Toxicity DNA deoxyribonucleic acid FDA Food and Drug Administration GBM Glioblastoma GCP Good Clinical Practice GLP Good Laboratory Practice Ht Height IB I kappa B kinase; cytokine response kinase that activates  transcription factor NF-kappa b at serine 32 and 36 ICAM-1 intercellular adhesion molecule 1 ICH International Conference on Harmonisation IEC Independent Ethics Committee IND Investigational New Drug IRB Institutional Review Board IV Intravenous IB I kappa B alpha-associated protein kinase Kg Kilogram Ki inhibitory constant Lbs Pounds 2 square meters m Mg Milligram Min Minute mL Milliliter   |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|  
| VELCADE (bortezomib) for Injection  UCLA Neuro-Oncology Program  Abbreviation Definition mm3 cubic millimeters Mmol Millimole MTD Maximum Tolerated Dose NCI National Cancer Institute NF-B nuclear factor-B Ng Nanogram nM Nanomole p21 p21(ras) farnesyl-protein transferase p27 cyclin-dependent kinase inhibitor p53 tumor suppressor protein with molecular weight of 53 kDa PR Partial response RT Radiation therapy SAE SQ TMZ serious adverse event subcutaneous temozolomide UCLA University of California at Los Angeles US United States USP United States Pharmacopeia VCAM-1 vascular cell adhesion molecule 1 w/w weight-to-weight ratio Wt Weight   |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
untitled h1
1 introduction and study rationale

The incidence of primary malignant brain tumors in the United States (US) is about 17,000 per year, with approximately 10,000 deaths per year (Wrensch, Minn et al. 2002). Glioblastoma is the most frequent, accounting for ~40% of all primary malignant brain tumors. It is the most aggressive form of brain cancer. Although they are relatively uncommon, malignant brain tumors account for significant mortality in the US. Despite optimal treatment with surgery, radiation therapy, and chemotherapy, the prognosis remains poor. Recently, a phase III randomized trial comparing radiation alone with combined temozolomide and radiation followed by 6 cycles of temozolomide showed that the addition of temozolomide increased median survival from 12.1 months to 14.6 months, increasing 2year survival rates from 10.4% to 26.5% (Stupp, Mason et al. 2005). These results have established adjuvant temozolomide and radiation as the standard of care for newly-diagnosed glioblastoma. Nonetheless, there is clearly a need for improvement given that this regimen is associated with a two-year survival of only 26%. The proposed trial will evaluate whether the addition of bortezomib to radiation and temozolomide can be safely tolerated, and whether this combination has increased efficacy in the treatment of newly-diagnosed glioblastoma. The major safety issues that are anticipated to require close monitoring are myelotoxicity (particularly thrombocytopenia), and any unpredicted neurological side effects secondary to bortezomib and brain radiation. Accumulating evidence indicates that NF-kB may be constitutively active in glioblastoma (Raychaudhuri, Han et al. 2007). NF-kB may potentially have a key role in tumor processes such as invasion, suppression of apoptosis, angiogenesis, proliferation, and chemotherapeutic and radiation resistance. Thus, targeting NF-kB activation has emerged as an anti-tumor strategy. Bortezomib is a reversible inhibitor of the chymotrypsin-like activity of the 26S proteasome in mammalian cells. The 26S proteasome is a large protein complex that degrades ubiquitinated proteins. The ubiquitin-proteasome pathway plays an essential role in regulating the intracellular concentration of specific proteins, thereby maintaining homeostasis within cells. Inhibition of the 26S proteasome prevents this targeted proteolysis, which can affect multiple signaling cascades within the cell.  
Bortezomib has gained United States Food and Drug Administration (US FDA) approval for myeloma in the relapsed and frontline setting, and in relapsed mantle cell lymphoma. Its primary mechanism of action is thought to be mediated by repression of NF-kB signaling by stabilization of IkB (Orlowski and Kuhn 2008). There is preclinical evidence demonstrating activity of bortezomib against glioblastoma (Yin, Zhou et al. 2005; Styczynski, OlszewskaSlonina et al. 2006). Bortezomib causes growth arrest of human GBM cell lines and GBM explants via NF-kB inhibition that can be enhanced by TNF alpha or TNF-related apoptosisinducing ligand (TRAIL) (Yin, Zhou et al. 2005). The clinical trial experience in actual patients has not been published, and is limited to recurrent patients (tamoxifen/bortezomib (Cedars-Sinai), temozolomide/bortezomib (City of Hope), and bevacizumab/bortezomib (Duke)) Bortezomib and Concurrent External Beam Radiation (Universty of Colorado), Bortezomib with Concurrent Fixed Dose Paclitaxel and Radiation (University of Colorado), Concomitant Bortezomiband Radiation (NCI), Bortezomib as a Radiosensitizer in Patients with Metastatic Melanoma to the Brain who Require Whole Brain Radiation (University of Michigan), Bortezomib, Paclitaxel, Carboplatin, and Concurrent Thoracic Radiation Therapy (NCCTG). In other tumor types, there is evidence of enhancement of either temozolomide or radiotherapy with concurrent administration of bortezomib (Russo, Tepper et al. 2001; Amiri,  
Horton et al. 2004; Edelman 2005). For example, melanoma cells *in vitro* and in the context of murine models were significantly more sensitive when treated with the combination of bortezomib and temozolomide compared to temozolomide alone (Amiri, Horton et al. 2004).  
Increased levels of NF-kB activity has been implicated in tumor resistance to temozolomide
(Bredel, Bredel et al. 2006; Yamini, Yu et al. 2007). Recently, bortezomib with concurrent radiotherapy and temozolomide has been studied in a phase I trial for central nervous system malignancies, including newly-diagnosed and recurrent malignant gliomas (Kubicek, Werner-Wasik et al. 2008). Only temozolomide was continued after radiation for maintenance. At the highest dose used (1.3 mg/m2, days 1, 4, 8 and 11 of a 21 day cycle given twice), no dose-limiting toxicities were reported. The most frequent toxicities were Grade 1 and 2 stomatitis, erythema, and alopecia. Grade 3 toxicities reported were headache, neuropathy, syncope, hyponatremia, and dyspnea. This study adds to the currently limited experience treating humans with concurrent bortezomib and radiation. In preclinical models, bortezomib is a radiosensitizer (Davies, Lara et al. 2007). There are ongoing studies utilizing the combination of bortezomib and radiation therapy (RT) for a variety of solid tumors. In a study utilizing bortezomib (0.6 mg/ m² twice weekly) and reirradiation for recurrent head-and-neck squamous cell carcinoma (HNSCC), there was no clear relationship between the bortezomib/RT combination and observed DLTs (Van Waes, Chang et al. 2005). Particularly, no excessive mucositis was observed. In case reports in which multiple myeloma was treated with concurrent RT and bortezomib, apparent increased local GI toxicity was observed (Berges, Decaudin et al. 2008). In summary, the rationale for the study is based on: 1) current inadequacy of standard of care therapy for newly-diagnosed glioblastoma, 2) preclinical evidence indicating activity of bortezomib against glioblastoma and possible synergism with temozolomide and/or radiation, and 3) demonstrated feasibility of such a similar study conducted at UCLA and the possibility of more rapid enrollment and 4) tissue collection (serum and tumor tissue) and banking for correlative studies aimed at understanding biomarkers and mechanisms of tumor response to bortezomib within this context.
untitled h1
1.2 velcade (bortezomib) for injection

VELCADE (bortezomib) for Injection UCLA Neuro-Oncology Program the state of the s the content of the conte ting the content of the the content of the conte the content of the conte e and the state of e and the second of the second the second of the second the second the second the the content of the conte the content of the conte the state of the s the state of the s e and the second of the the content of the conte the content of the conte the content of the conte the content of the conte ting the content of the AAA
e and the state of AAA  
e and the second of the second the second of the second the second the second the the state of the s the state of the s ting and the e and the state of the state of the s the content of the conte the content of the conte the state of the s the state of the s ting the content of the e and the second of the the content of the conte the state of the s the content of the conte the state of the s the content of the conte AAAA
the state of the s the state of the s the content of the conte
untitled h1
1.2 velcade (bortezomib) for injection

ting the content of the the content of the conte the state of the s the state of the s the state of the s ting the content of the e and the second of the the state of the s the content of the conte the state of the s ting the content of the the content of the conte e and the state of ting the content of the the state of the s ting the content of the the content of the conte the state of the s the content of the conte the content of the conte the state of the s e and the second of the  
AAA
the content of the conte  
the state of the s e and the state of VELCADE (bortezomib) for Injection UCLA Neuro-Oncology Program the content of the conte ting the content of the the content of the conte the state of the s the state of the s ting the content of the e and the second of the second the second of the second the second the second the second the second the second the second the second the second second second second second se the content of the conte and the state of t the state of the s the content of the conte the content of the conte ting the content of the the content of the conte ting the content of the the content of the conte ting the content of the the content of the conte e and the second of the second the second of the second the second the second the the state of the s e and the state of the state of the s the content of the conte the state of the s the content of the conte the content of the conte AAAA
e and the second of the ting the content of the e and the second of the the state of the s e and the second of the second the second of the second the second the second the AAAA
CONSIDER CONSIDER  
the state of the s the content of the conte VELCADE (bortezomib) for Injection UCLA Neuro-Oncology Program  
  
  
  
CONTROL
1 1 1 CONTROL
I  
  
n CONTROL
ting the content of the  
VELCADE (bortezomib) for Injection UCLA Neuro-Oncology Program the state of the s ting the content of the the content of the conte the state of the s ting the content of the e and the second of the second the second of the second the second the second the e and the second of the e and the content of the the content of the conte  
ting the content of the ting the content of the e and the second of the second the second of the second the second the second the second the second the second the second the second the second the second theme to the second e and the second of the second the second of the the content of the conte ting the content of the the content of the conte ting the content of the  
AAA  
ting the content of CONTROL  
ting and I  
e and the second of the second the second of the second the second the second the ting the content of ting and the state the state of the s the content of the conte e and the second of the second the second of the second the second the second the ting the content of the ting the content of the the content of the conte ting the content of the ting the content of the ting the content of the ting the content of the ting the content of the ting the content of the ting the content of the the content of the conte e and the state of e and the state of the content of the conte the state of the s the content of the conte the content of the conte ting the content of the ting the content of the AAA
e a sense of the s e and the second of the second the second of the second the second the second the e and the second of the second the second of the second the second the second the the content of the conte ting the content of the
untitled h1
velcade (bortezomib) for injection

UCLA Neuro-Oncology Program the content of the conte ting the content of the ting the content of the e and the state of the state of the s the state of the s the content of the conte the content of the conte the content of the conte ting the content of the e and the second of the second the second of the second the second the second the the content of the conte the state of the s the content of the conte the content of the conte the content of the conte the state of the s the content of the conte the content of the conte ting the content of the the content of the conte ting the content of the the content of the conte the content of the conte the content of the conte the content of the conte the content of the conte the content of the conte the content of the conte ting the content of the the content of the conte the content of the conte ting the content of the the content of the conte the content of the conte the state of the s the content of the conte e and the second of the second the second of the second the second the second the e and the state of the content of the conte e and the second of the second the second of the second the second the second the second the second the second the second the second the second the second the second theme to ting the content of the VELCADE (bortezomib) for Injection UCLA Neuro-Oncology Program the content of the conte the state of the s the state of the s the content of the conte ting the content of the the state of the s the state of the s the state of the s the content of the conte the state of the s the content of the conte the the content of the conte the content of the conte the state of the s the state of the s ting the content of the e and the state of the state of the s the content of the conte e and the state of the content of the conte the content of the conte ting the content of the e and the state of the state of the s e and the content of the e and the content of the the content of the conte the state of the s the content of the conte ting the content of the the state of the s the content of the conte the content of the conte the state of the s the state of the s the state of the s the content of the conte ting the content of the ting the content of the the state of the s
untitled h1
1.3 temozolomide (see product insert)

Temozolomide is an oral DNA alkylating agent that is FDA approved for the treatment of malignant gliomas. It is a derivative of dacarbazine and is rapidly converted systemically to MTIC. It interferes with DNA replication via alkylation of specific sites of the nucleotide backbone. Perhaps the most important site is on the O6 position of guanine. Alkylation of this site can be repaired by the enzyme, O-6-methylguanine-DNA methyltransferase (MGMT). Promoter methylation of MGMT has emerged as a marker of response to temozolomide. 1.3.2 Nonclinical Pharmacology Not applicable 1.3.3 Nonclinical Toxicity Not applicable 1.3.4 Clinical Pharmacokinetics and Pharmacodynamics See product insert. http://www.spfiles.com/pitemodar.pdf 1.3.5 Clinical Experience See product insert. http://www.spfiles.com/pitemodar.pdf 1.3.6 Potential Risks of Temozolomide See product insert. http://www.spfiles.com/pitemodar.pdf
untitled h1
1.4 study rationale and selection

The present proposal seeks to investigate whether beneficial effects can be detected when bortezomib is combined with first-line treatment with temozolomide/XRT in patients with newly-diagnosed glioblastoma. Accumulating evidence indicates that NF-kB may be constitutively active in glioblastoma (Raychaudhuri, Han et al. 2007). Given the potential for NF-kB to have a key role in tumor processes such as invasion, suppression of apoptosis, angiogenesis, proliferation, and chemotherapeutic and radiation resistance, targeting NF-kB activation has emerged as an anti-tumor strategy. Bortezomib is a proteasomal inhibitor that has gained FDA approval for both myeloma and relapsed mantle cell lymphoma. Its primary mechanism of action is thought to be mediated by repression of NF-kB signaling by stabilization of IkB (Orlowski and Kuhn 2008). There is preclinical evidence of activity of bortezomib against glioblastoma (Yin, Zhou et al. 2005; Styczynski, Olszewska-Slonina et al. 2006). Bortezomib causes growth arrest of human GBM cell lines and GBM explants via NF-kB  
inhibition, and could be enhanced by TNF alpha or TNF-related apoptosis-inducing ligand (TRAIL) (Yin, Zhou et al. 2005). The clinical trial experience in actual patients has not been published and is limited to recurrent patients (tamoxifen/bortezomib (Cedars-Sinai),
temozolomide/bortezomib (City of Hope), bevacizumab/bortezomib (Duke). In other tumor types, there is evidence of enhancement of either temozolomide or radiotherapy with concurrent administration of bortezomib (Russo, Tepper et al. 2001; Amiri, Horton et al. 2004; Edelman 2005). Increased levels of NF-kB activity has been implicated in tumor resistance to temozolomide (Bredel, Bredel et al. 2006; Yamini, Yu et al. 2007). Recently, bortezomib with concurrent radiotherapy and temozolomide has been studied in a phase I trial for central nervous system malignancies, including newly-diagnosed and recurrent malignant gliomas (Kubicek, Werner-Wasik et al. 2008). Only temozolomide was continued after radiation for maintenance. At the highest dose used (1.3 mg/m2, days 1, 4, 8 and 11 of a 21 day cycle given twice), no dose-limiting toxicities were reported for bortezomib. The most frequent toxicities were Grade 1 and 2 stomatitis, erythema, and alopecia. Grade 3 toxicities reported were headache, neuropathy, syncope, hyponatremia, and dyspnea. This study adds to currently limited experience treating humans with concurrent bortezomib and radiation. In preclinical models, bortezomib is a radiosensitizer (Davies, Lara et al. 2007). There are ongoing studies utilizing the combination of bortezomib and RT for a variety of solid tumors. In a study utilizing bortezomib (0.6 mg/ m² twice weekly) and re-irradiation for recurrent head-and-neck squamous cell carcinoma (HNSCC), there was no clear relationship between the bortezomib/RT combination and observed DLTs (Van Waes, Chang et al. 2005). Particularly, no excessive mucositis was observed. In case reports in which multiple myeloma was treated with concurrent RT and bortezomib, apparent increased local GI toxicity was observed (Berges, Decaudin et al. 2008). Another feature of this trial is the requirement for frozen and paraffinized patient tumor tissue for molecular characterization. We have recently completed enrollment of a similar trial in which frozen tumor tissue was required (Lai, Filka et al. 2008). This is a 70-patient trial examining the safety and efficacy of upfront bevacizumab, temozolomide, and radiaton for the treatment of newly-diagnosed glioblastoma. The detailed tissue interrogation for the bevacizumab/TMZ/RT has not yet begun, although fairly detailed plans have been formulated. Planned assays for the bevacizumab/TMZ/RT study include MGMT promoter methylation and immunohistochemistry VEGF and VEGFR immunohistochemistry gene expression, SNP (for copy number), and methylation microarray based profiling. We anticipate that much of the experience and information gained from characterizing this tissue will be directly applicable to the proposed patient sample set. In summary, the rationale for the study is based on: 1) current inadequacy of standard of care therapy for newly-diagnosed glioblastoma, 2) preclinical evidence indicating activity of bortezomib against glioblastoma and possible synergism with temozolomide and radiation, and 3) demonstrated feasibility of such a similar study conducted at UCLA and the possibility of more rapid enrollment and tissue interrogation leading to understanding of biomarkers and mechanisms of tumor response to bortezomib within this context.  
The selection of RT and TMZ dosing is based entirely on the Stupp protocol for newlydiagnosed GBM (Stupp, Mason et al. 2005). Based on the recent phase I study, patients will receive 1.3 mg/ m²/day on days 1, 4, 8, 11, 29, 32, 36, and 39 during radiation (Kubicek, Werner-Wasik et al. 2008). The 1.3 mg/ m²/day dose (days 1, 4, 8, and 11 of a 28 day cycle) will be the maintenance dose for all patients. This is the dose previously used in combination  
with TMZ maintenance therapy without evidence of significant toxicity (personal communication, Dr. Portnow, City of Hope, Duarte, CA).
untitled h1
2 study objectives

This phase II study will have a **Radiation phase** with bortezomib in combination with temozolomide/radiation followed by a **Maintenance phase** of bortezomib and temozolomide following completion of radiation for 2 years (24 28-day cycles).
untitled h1
2.1 primary objective the primary

Estimate the overall survival Investigate the safety and tolerability of this drug combination (bortezomib with temozolomide/radiation followed by bortezomib and temozolomide maintenance for 2 years if there is no progression, in which case both drugs will be stopped, and the patient will obtain routine MRI surveillance until progression) in newlydiagnosed patients with glioblastoma.  
2.2 **Secondary Objectives**
The secondary objectives of this study are to:  
Investigate further the safety and tolerability of bortezomib/temozolomide/radiation followed by bortezomib/temozolomide.  
Collect frozen and paraffinized patient tumor tissue for MGMT promoter methylation analysis and IDH1 genotyping and for correlative studies. Tissue must be obtained in all study patients from the original surgery, and in those patients who will be undergoing resection at time of treatment failure and during the follow-up period.
untitled h1
3 investigational plan 3.1 overall

This study will be a multi-center, open-label, phase II study assessing safety and efficacy in which adult newly-diagnosed GBM patients that have had no prior therapy other than surgery will receive bortezomib, temozolomide, and radiation all starting on day 1 (+/- 2 days) of study. Day 1 of the study must be no sooner than 2 weeks from surgery and no longer than 6 weeks after surgery, followed by bortezomib and temozolomide after completion of fractionated radiation for up to 24 additional cycles if no tumor growth is seen. At this point, both bortezomib and temozolomide will be discontinued and patients will be monitored with routine MRI surveillance till progression. Patients will be treated with bortezomib 1.3 mg/ m² SQ on days 1, 4, 8, 11, 29, 32, 36, and 39 and temozolomide 75 mg/m2 daily during radiation. Bortezomib will be administered beginning on the first day of radiation with temozolomide. External beam fractionated regional radiation will be given on consecutive week days at 200 cGy daily doses to a total dose of 6000 cGy (see Appendix 8.12). Although the preferred two week rest period contrasts with the 4 week rest period used in the phase III radiation/temozolomide trial (Stupp, Mason et al. 2005), we will attempt to shorten the rest period to 2 weeks in order to minimize treatment delay. This shortened rest period has been safely used in a study examining the effect of upfront temozolomide and cis-retinoic acid and radiation (Butowski, Prados et al. 2005). The 2-week rest period is also consistent with our current clinical practice. However, if the patient has fatigue, bone marrow suppression, or other toxicities, the temozolomide rest period may be extended up to six weeks. After a 2-6 week rest (for temozolomide and bortezomib) following completion of radiation therapy, temozolomide will be restarted at 150 mg/ m²/day day 1-5 of every 28 day cycle. If this dose is tolerated, subsequent cycles will be given at 200 mg/ m²/day. Bortezomib will be given at a dose of 1.3 mg/m²on days 1, 4, 8, and 11 of a 28 day cycle commencing on the first day of temozolomide. Temozolomide will not be increased greater than 200 mg/ m²/day. No increases in bortezomib will be allowed. Treatment with bortezomib and temozolomide will continue for 24 additional 28 day cycles following completion of radiation therapy if there is no evidence of progression. At that time, both bortezomib and temozolomide will be stopped if there is no evidence of disease progression. If unacceptable toxicities after the first 12 cycles are observed per investigator's discretion, the bortezomib dosing schedule may be changed to 1.3 mg/m2 weekly for 3 weeks on and 1 week off, with the possibility of further reduction if necessary to 1.3 mg/m2biweekly. Overall survival, 6-month progression free survival, and time to progression will be reported. An interim analysis will be conducted on the first 10 patients. This patient cohort will be monitored for unanticipated or unacceptable toxicities related to the combination of bortezomib and brain radiation, as well as focusing on delayed effects of radiation 4 weeks after the completion of radiation therapy. Specifically, we will be looking for increased rates of brain hemorrhage, necrosis, and scalp wound healing problems. Common adverse events such as myelosuppression or deep venous thrombosis (occurring in ~30% of patients with high-grade glioma (Robins, Won et al. 2006)) will also be carefully reviewed to determine whether they are related to the bortezomib combination. Unless a clear causal relationship is demonstrated, such adverse advents will not be considered a toxicity due to bortezomib/RT combination therapy.
untitled h1
clinical and laboratory evaluations pre-treatment

-A complete history and physical (to include height, weight, and BSA), vital signs
(including blood pressure) and neurological examination (to include mental status, neurological function, and documentation of the patients Karnofsky performance status), as well as neuro-imaging documentation of disease shall be performed on all patients within 21 days prior to initiation of treatment. In patients that have had immediate post-operative MRI scans, this will likely necessitate a repeat baseline MRI scan if treatment is initiated much greater than 21 days after resection.  
-Pre-study laboratory tests must include CBC with differential and platelets, serum creatinine, BUN, total bilirubin, SGOT, SGPT, serum electrolytes (including Na, Cl and K),PT, PTT, INR, glucose, albumin, alkaline phosphatase, calcium, total protein, urine test and creatinine clearance (calculated), anti-convulsant levels if applicable, and a serum pregnancy test for women of childbearing potential. Pre-study laboratory tests must be obtained within 14 days of initiation of treatment. Any abnormal pre-study laboratory tests must be rechecked within 48 hours of initiating therapy.  
- Documentation of tumor diagnosis. Following registration, slides from the preregistration biopsy must be submitted to UCLA for review.  
- Unstained paraffin block or slides from surgical samples: A paraffinized tumor block must be obtained in all study patients from the surgery in which frozen tissue was collected, and in those patients who will be undergoing resection at time of treatment failure and during the follow-up period. If such a tumor block cannot be obtained then 1 H & E stained slide and 20 unstained paraffin slides may be submitted instead. Collection of an unstained paraffin block is optional in the follow-up part of the trial. The paraffin block/slides will be used for MGMT methylation analysis and IDH1 genotyping.  
-Frozen surgical samples: A frozen tumor block sample will be obtained in all study patients at the time of surgery, and in those patients who will be undergoing resection at time of treatment failure and during the follow-up period. Collection of frozen tissue is optional in the follow-up part of the trial. Frozen tissue will be used to verify MGMT methylation and IDH1 genotyping and for correlative studies.  
  
  
Evaluations During Treatment A. Evaluations to be obtained prior to and during the concomitant therapy with bortezomib, temozolomide and radiation:  
- Laboratory studies: CBC with differential and platelets will be performed weekly during radiation treatment. Creatinine, BUN, total bilirubin, SGOT, glucose, albumin, alkaline phosphatase, SGPT, calcium, total protein, serum electrolytes (including Na, Cl and K) will be performed every 2 weeks during radiation.  
- Plasma and serum collection prior to each treatment cycle on day 1 of each 28 days treatment cycle.  
- Whole blood sample at initiation of treatment.
untitled h1
plasma sample collection and preparation

Collect 5 mL of whole blood into a CTAD (B-D Cat \#367947 Hemogard, 4.5 mL tube) blue top vacutainer tube, being careful to minimize agitation of the sample and using the largest-bore needle that is feasible for the patient. Mix by gently inverting the tube 4 times. Centrifuge at 2000 x g for 15 minutes at room temperature within 1 hour of draw. Within 30 minutes after centrifugation, draw off plasma very slowly with transfer pipette to within 0.5 cm of the buffy coat, taking great care not to disturb the buffy coat. (Any contamination may invalidate the assay.) Pipette the plasma specimen equally into plastic cryovials. Do not transfer more than 1.5 mL into each tube. Label tube with subject identification number, initials, and date of specimen collection.
untitled h1
serum sample collection and preparation

Collect 5 mL of blood in one red top tube. Immediately mix by inverting tubes 4 times. Complete the pre-printed labels with subject identification numbers, initials, and date of specimen collection. Allow serum to clot for 30 minutes. Spin at 2000 x g for 15 minutes to separate clot from serum. Pipette no more than 1.5 mL of serum specimen into plastic cryovials. All specimens must be stored frozen at -20 C (or colder) until pickup.
untitled h1
whole blood sample collection and

1. Ensure that the PAXgene Blood DNA Tube is at room temperature (1825°C)prior to use and properly labeled with patient identification. 2. The PAXgene Blood DNA Tube should be the last tube drawn. 3. After blood collection, gently invert the PAXgene Blood DNA Tube 8 - 10 times.  
4. Freeze PAXgene Blood DNA Tubes upright in a wire rack or horizontally in a plastic bag at -20 C (or colder).Do not freeze tubes upright in a Styrofoam®
collection tray as this may cause the tubes tocrack. - A neurologic exam must be performed every two weeks during radiation therapy, to include: the patient's Karnofsky performance status, neurological function, and mental status. A general physical exam must also be performed every two weeks during radiation, to include: examination of the skin within the treatment portal And evaluation for adverse events These adverse events will be documented in the medical record, on the Flow sheet CRF, and reported to the principal investigator. Adverse events in subsequent cycles will be reported prior to the beginning of each cycle. Height, weight, and BSA must be evaluated prior to each cycle.  
- MRI of the brain with and without gadolinium contrast is required within 21 days of Day 1 of the study. A postoperative MRI scan within 96 hours of surgery is also preferred.  
| Evaluation during the radiation therapy:  Prior to   | Every             | Every      | At week   |         |    |
|------------------------------------------------------|-------------------|------------|-----------|---------|----|
| Procedures                                           | Treatment         | Every week | 2 weeks   | 4 weeks | 6  |
| History, physical exam,                              | g                 | X          | X         | X       |    |
| height/weight                                        | X g               | X          | X         | X       |    |
| Neurologic Evaluation                                | X a               | X          | X         | X       |    |
| Routine blood test                                   | X                 |            |           |         |    |
| Urine test                                           | X                 |            |           |         |    |
| Research blood testf                                 | X f               | X          |           |         |    |
| MRI head                                             | X h               |            |           |         |    |
| Pregnancy test                                       | X b               |            |           |         |    |
| Pathology slides/frozen tissue                       | X                 | X          |           |         |    |
| Study Treatment with                                 | Days 1, 4, 8, 11, |            |           |         |    |
| Bortezomibd                                          | 29, 32, 36, 39    |            |           |         |    |
| Study Treatment with                                 | X                 |            |           |         |    |
| Temozolomidec                                        | Days 1 - 42       |            |           |         |    |
| Radiation therapye                                   | X                 |            |           |         |    |
| for 6 weeks                                          |                   |            |           |         |    |  
a Must be obtained within 14 days prior to starting treatment (weekly during radiation therapy).  
b for female patients of childbearing potential cTemozolomideDay 1 –42 during radiation therapy. dBortezomibon day 1, day 4, day 8 , day 11, day 29, day 32, day 36 and day 39 during radiation therapy.  
e Radiotherapy will be administered in 2Gy/day fractions delivered 5 days per week to a total dose of 60Gy over a six week period.  
fResearch blood test (on day 1 of a 28 day treatment cycle.)
g Must be obtained within 14 days prior to treatment and every 2 weeks during radiation therapy h Must be obtained within 21 days of Day 1 of the study.  
B. Evaluations to be obtained after completion of radiation, during maintenance phase with bortezomib and temozolomide:  
- In general, a cycle is defined as a four-week interval starting from the first bortezomib/temozolomide dose given post-radiation. If temozolomide is started first (if, for example, bortezomib is delayed because of peripheral neuropathy), wait to begin bortezomib until day 1 of the next four-week cycle. Always begin bortezomib on day 1 of a cycle, never mid-cycle.  
- CBC with differential and platelets, creatinine, BUN, total bilirubin, SGOT,
glucose, albumin, alkaline phosphatase, SGPT, calcium, total protein, and serum electrolytes (including Na, Cl and K) must be performed on days 21 and 28 (+/- 3 days). If cycle is held for any reason, labs must be repeated again before cycle initiation if labs greater than 3 days from Day 1.  
- A neurologic exam must be performed every two weeks during radiation therapy and then every four weeks after radiation is completed (prior to the start of each new cycle). The exam must include: patient's Karnofsky performance status, neurological function, and mental status. A general physical exam must also be performed every four weeks after radiation is completed, to include: height, weight, BSA, and evaluation for any adverse events. Adverse events will be reported prior to the beginning of each cycle.  
- MRI of the brain with and without gadolinium contrast is required within 21 days of Day 1 of the study. Then MRI will be performed 2 weeks 7 days after completion of radiation, and then every 8 weeks 7 days. CT scanning with and without contrast may be substituted if an MRI is medically contraindicated.  
| Evaluation to be Obtained During Bortezomib and Temozolomide after radiation  Studies Day 1 Day 21   | Day 29   |    |    |
|------------------------------------------------------------------------------------------------------|----------|----|----|
| History, physical exam, height/weight, toxicity                                                      | X        | X  |    |
| Neurologic Evaluation                                                                                | X        | X  |    |
| Routine blood test                                                                                   | X        | X  | X  |
| Research blood test a                                                                                | X        | X  |    |
| MRI head b Temozolomide                                                                              | X        |    |    |
| Days 1 - 5                                                                                           | X        |    |    |
| Bortezomib                                                                                           | X        |    |    |
| Days 1, 4, 8, 11                                                                                     | X        |    |    |
| a Research blood test on day 1 of a 28 day treatment cycle.                                          |          |    |    |  
- All relevant information regarding drug doses, concomitant medications and doses, measurable lesions, tumor response, laboratory examinations, and treatment-related toxicities shall be documented in the patient's medical record and case report form flow sheets.  
- All patients will be followed for survival. Patients who progress will be followed for survival every 4 months. Patients who complete therapy and do not progress should be followed every 2 months for 12 months, every 3 months for the next 12 months, every 4 months for the next 12 months, and then every 6 months until progression is determined. They should then be followed for survival every 4 months. Patients will be asked to provide pathology slides and frozen tissue if they undergo elective surgery during the follow-up period. Collection of an unstained paraffin block and frozen tissue is optional in the follow-up part of the trial. Subjects will need to sign a separate consent form if they agree to donate the tissue samples.  
- If patients remain on study drug for greater than one year, the study evaluations for neurologic exam and physical exam may be changed to every 8 weeks.
untitled h1
central review of mri scans

Post-Treatment Evaluations  
Patients taken off study due to unacceptable toxicities or completion will be followed with a brain MRI at a minimum of every 2 months until progression is determined, and a neurological examination at a minimum of every 4 months. A study flow chart is provided in section 0.
untitled h1
3.2 selection of patients

The total number of patients to be enrolled on this study is: 50. Enrollment is defined as the first day of VELCADE treatment (i.e., Day 1 of Cycle 1). This study was designed to include women and minorities, but was not designed to measure differences of intervention effects. Males and females will be recruited with no preference to gender. No exclusion to this study will be based on race. Minorities will actively be recruited to participate.  
3.2.1 Inclusion Criteria Each patient must meet all of the following inclusion criteria to be enrolled in the study:
Voluntary written informed consent obtained before performance of any study-related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the subject at any time without prejudice to future medical care. All  
patients must sign an informed consent approved by the Institutional Review Board indicating that they are aware of the investigational nature of this study. Patients must also sign an authorization for the release of their protected health information.  
Female subject is post-menopausal for at least 1 year before the Screening visit, surgically sterilized, or if they are of childbearing potential, agree to practice 2 effective methods of contraception, at the same time,(i.e., a hormonal contraceptive, intra-uterine device, diaphragm with spermicide, condom with spermicide, or abstinence) from the time of signing the informed consent through 30 days after the last dose of study treatment, OR agree to completely abstain from heterosexual intercourse.  
Male subject even if surgically sterilized (ie, status postvasectomy), whoagrees to practice effective barrier contraception during the entire study treatment period and through 30 days after the last dose of study treatment, or agree to completely abstain from heterosexual intercourse.  
Patients will have a histologically proven intracranial glioblastoma multiforme (GBM) or gliosarcoma (GS). This includes treatment-naïve patients with prior tissue diagnoses of lower grade gliomas that have been upgraded to GBM after repeat resection.  
Cranial MRI or contrast CT must have been performed within 21days of study entry. The use of MRI rather than CT is preferred. The same type of scan, i.e., MRI or CT must be used throughout the period of protocol treatment for tumor measurement. If the surgical procedure was a resection, cranial MRI or contrast CT performed within 96 hours of resection is preferred, but not required. Patients without measurable or assessable disease are eligible.  
Patients must begin partial brain radiotherapy no sooner than 2 weeks and no later than 6 weeks from the surgery in which tissue was collected. Patients with GBM diagnosis from surgeries in which tissue was not collected will be eligible after repeat surgery is performed to collect tissue, as long as no treatment has been initiated prior to the surgery in which tissue was collected. In this case, initiation of treatment must begin within three to six weeks from the last surgery. Patients may have radiotherapy administered at outside facilities according to the specified guidelines (Appendix 8.12). Radiotherapy must be given by external beam to a partial brain field in daily fractions of 2.0 Gy, to a planned total dose to the tumor of 60.0 Gy in accordance with Appendix 8.12 Stereotactic radiosurgery and brachytherapy will not be allowed.  
Patients must be willing to forego other drug therapy against the tumor while being treated with bortezomib, temozolomide, and radiation, and subsequently bortezomib and temozolomide.  
Patients must be > 18 years old, and with a life expectancy > 8 weeks.  
Patients must have a Karnofsky performance status of > 60.  
Patients must have adequate bone marrow function (WBC > 3,000/µl, ANC > 1,500/mm3, platelet count of > 100,000/mm3, and hemoglobin > 10 gm/dl) and the test must be performed within 14 days prior to registration. Eligibility level for hemoglobin may be reached by transfusion.  
Patients must have adequate liver function (SGOT < 2.5 times ULN and bilirubin < 1.5 times ULN) and the test must be performed within 14 days prior to registration.  
Patients must have adequate renal function (creatinine < 1.5 mg/dL) before starting therapy and the test must be performed within 14 days prior to registration.
3.2.2 Exclusion Criteria Patients meeting any of the following exclusion criteria are not to be enrolled in the study.  
Patient has a platelet count of <100 109/L within 14 days before enrollment. Patient has an absolute neutrophil count of <1.5  109/L within 14 days before enrollment.  
Patient has a calculated or measured creatinine clearance of <20 mL/minute within 14 days before enrollment.  
Patient has Grade 2 peripheral neuropathy within 14 days before enrollment. Myocardial infarction within 6 months prior to enrollment or has New York Heart Association (NYHA) Class III or IV heart failure (see section 8.4), uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities. Prior to study entry, any ECG abnormality at screening has to be documented by the investigator as not medically relevant.  
Patient has hypersensitivity to bortezomib, boron, or mannitol. Female subject is pregnant or breast-feeding. Confirmation that the subject is not pregnant must be established by a negative serum -human chorionic gonadotropin (-
hCG) pregnancy test result obtained during screening. Pregnancy testing is not required for post-menopausal or surgically sterilized women. Women with reproductive potential must practice adequate contraception for the duration of the study. The anti-proliferative effects of the investigational agent may be detrimental to the developing fetus or nursing infant.  
Participation in clinical trials with other investigational agents not included in this trial, within 14 days of the start of this trial and throughout the duration of this trial.  
Serious medical or psychiatric illness likely to interfere with participation in this clinical study including, but not limited to, ongoing or active infection requiring IV antibiotics, psychiatric illness/social situations that would limit compliance with study requirements, or disorders associated with a significant immunocompromised state (HIV, SLE, etc.);
Diagnosed or treated for another malignancy within 3 years of enrollment, with the exception of complete resection of basal cell carcinoma or squamous cell carcinoma of the skin, an in situ malignancy (such as cervical), or low-risk prostate cancer after curative therapy. Patients must be in complete remission and off of all therapy for that disease for a minimum of 3 years.  
Patients must not have received previous radiotherapy to the brain. Patients must not have received cytotoxic drug therapy, non-cytotoxic drug therapy, or experimental drug therapy directed against the brain tumor. Patients who received Gliadel wafers will be excluded. Patients may have received or be receiving corticosteroids, AED's, analgesics, and other drugs to treat symptoms or prevent complications.  
Since VELCADE is partially metabolized by inducers of CYP450 3A4 such as Enzymeinducing anti-epileptic drugs (EIAED), patients on EIAED must be transitioned to nonEAIED at least 2 weeks prior to initiation of treatment.
Patients must not have received previous radiotherapy to the brain.
untitled h1
general medical concerns

Patients must not have any significant medical illnesses that in the investigator's opinion cannot be adequately controlled with appropriate therapy or would compromise the patient's ability to tolerate this therapy.  
Patients receiving current, ongoing treatment with full-dose warfarin or its equivalent
(i.e., unfractionated and/or low molecular weight heparin) are NOT excluded (see 1.2.2). However, since Velcade is weak inhibitor of CYP450 2C19, close monitoring of INR will be required.  
Patients must not have any disease that will obscure toxicity or dangerously alter drug metabolism.  
No viral hepatitis (hep B surface ag positive), or active hepatitis C infection. History of stroke within the past 6 months.
untitled h1
3.3 study treatments 3.3.1 clinical

VELCADE (bortezomib) for Injection is a sterile lyophilized powder for reconstitution and is supplied in vials containing VELCADE and mannitol at a 1:10 ratio. For example, vials containing 3.5 mg of VELCADE contain 35 mg of mannitol.  
Temozolomide (TEMODAR®) is commercially available, manufactured and distributed by Schering-Plough, Inc. The oral capsules contain a white to light tan/light pink powder. The molecule is stable at acidic pH (<5), and labile at pH >7, hence TEMODAR can be administered orally. The prodrug, temozolomide, is rapidly hydrolyzed to the active 5-(3methyltriazen-1-yl)imidazole-4-carboxamide (MTIC) at neutral and alkaline pH values, with hydrolysis taking place even faster at alkaline pH. Each capsule contains either 5 mg, 20 mg, 100 mg, or 250 mg of temozolomide. The inactive ingredients for TEMODAR Capsules are lactose anhydrous, colloidal silicon dioxide, sodium starch glycolate, tartaric acid, and stearic acid. Gelatin capsule shells contain titanium dioxide. The capsules are white and imprinted with pharmaceutical ink. TEMODAR 5 mg: green imprint contains pharmaceutical grade shellac, anhydrous ethyl alcohol, isopropyl alcohol, n-butyl alcohol, propylene glycol, ammonium hydroxide, titanium dioxide, yellow iron oxide, and FD&C Blue \#2 aluminum lake. *TEMODAR 20 mg:* brown imprint contains pharmaceutical grade shellac, anhydrous ethyl alcohol, isopropyl alcohol, nbutyl alcohol, propylene glycol, purified water, ammonium hydroxide, potassium hydroxide, titanium dioxide, black iron oxide, yellow iron oxide, brown iron oxide, and red iron oxide. TEMODAR 100 mg: blue imprint contains pharmaceutical glaze (modified) in an ethanol/shellac mixture, isopropyl alcohol, n-butyl alcohol, propylene glycol, titanium dioxide, and FD&C Blue \#2 aluminum lake. *TEMODAR 250 mg:* black imprint contains pharmaceutical grade shellac, anhydrous ethylalcohol, isopropyl alcohol, n-butyl alcohol, propylene glycol, purified water, ammonium hydroxide, potassium hydroxide, and black iron oxide. Radiation-see Appendix 8.11
untitled h1
3.3.2 preparation handling and storage

Vials containing lyophilized VELCADE for Injection should be stored according to the label requirements. For the United States, store at USP Controlled Room Temperature which is 25ºC (77ºF); excursions permitted from 15 to 30ºC (59 to 86ºF). For Europe, do not store above 30ºC (86ºF). To date, stability data indicate that the lyophilized drug product is stable for at least 18 months when stored under the recommended conditions. Stability studies are ongoing, and Millennium Pharmaceuticals, Inc. will notify the investigator should this information be revised during the conduct of the study. VELCADE is cytotoxic. As with all cytotoxic drugs, caution is required when preparing and handling VELCADE solutions. Cytotoxic drugs should only be handled by staff specially trained in the safe handling of such preparations. The use of gloves and other appropriate protective clothing is recommended. In case of skin contact, wash the affected area immediately and thoroughly with soap and water for at least 15 minutes. If product contacts eye, immediately flush eye thoroughly with water for at least 15 minutes. Always contact a physician after any form of body contact. All materials that have been used for preparation should be disposed of according to standard practices. A log must be kept of all disposed materials. Drug is available in sterile, single use vials containing 3.5 mg of VELCADE. Each vial of VELCADE for Injection should be reconstituted under a laminar flow biological cabinet (hood) within eight hours before dosing with 3.5 mL of normal (0.9%) saline for intravenous or 1.4 mL for subcutaneous (see below), Sodium Chloride Injection USP, so that the reconstituted solution contains VELCADE at a concentration of 1 mg/mL. Prior to reconstitution the vials should remain in the cartons to protect them from light. Dissolution is completed in approximately 10 seconds. The reconstituted solution is clear and colorless, with a final pH of 5 to 6. Reconstituted VELCADE should be administered promptly and in no case more than 8 hours after reconstitution. All materials that have been used for preparation should be disposed of according to standard practices. A log must be kept of all disposed materials.
untitled h1
bortezomib destruction

Investigational bortezomib (expired or end of study) should be destroyed on site according to the institution's standard operating procedure. Be sure to document removal and destruction on drug accountability logs.
untitled h1
temozolomide

Tablets may be stored at 25°C (77°F); excursions permitted to 15-30°C (59-86°F). The commercial product has an expiration date on the label of the bottle. Drug administration and dosage schedule Administration and schedule of chemotherapy:
untitled h1
rt phase (beginning 2-6 weeks

Bortezomib1.3 mg/ m² SQ on days 1, 4, 8, 11, 29, 32, 36, and 39 during the 6 weeks of radiation.If dosing has to be delayed for any reason (such as holidays), subsequent treatments must be at least 3 days after prior dose. Temozolomide75 mg/m2/day PO starting on Day 1 during radiation and continuing for 42 consecutive days. External beam fractionated regional radiation will be given on consecutive week days at 200 cGy daily doses to a total dose of 6000 cGy.  
| Bortezomib   | 1.3mg/ m²     | SQ   | Days 1, 4, 8, 11, 29, 32, 36, 39 x 6 weeks   |
|--------------|---------------|------|----------------------------------------------|
| Temozolomide | 75 mg/m2/day  | PO   | Day 1 x 42 consecutive days                  |
| XRT          | 200 cGy doses | XRT  | Days Monday-Friday (total dose 6000 cGy)     |
untitled h1
maintenance phase (beginning after a

Bortezomib 1.3 mg/ m² SQ will given on days 1, 4, 8, and 11 of a 28 day cycle commencing on the first day of temozolomide. Day 1dosing of any cycle can be delayed for any nontoxicity reason (such as holidays) for up to 7 days, with the subsequent cycle starting no earlier than 28 days from the beginning of the delayed cycle. Similarly, if day 4,8, or 11 treatments need to be delayed for any non-toxicity related reason, then subsequent treatments must be at least 3 days after delayed dose.  
Temozolomide150 mg/m2/day day 1-5 of every 28 day cycle, increased to 200 mg/m2/day beginning in the second post RT cycle if no toxicities observed.  
Restaging with cranial MRI every 8 weeks, and continuing treatment for 24 additional 28 day cycles.  
| 1 st Cycle Bortezomib   | 1.3mg/ m²      | SQ   | Days 1, 4, 8, 11, of a 28 day cycle                           |
|-------------------------|----------------|------|---------------------------------------------------------------|
| Temozolomide            | 150 mg/m2 /day | PO   | Day 1-5 of a 28 day cycle                                     |
| 2 nd Cycle Bortezomib   | 1.3mg/ m 2     | SQ   | Days 1, 4, 8, 11, of a 28 day cycle for 24  additional cycles |
| Temozolomide            | 200 mg/m2 /day | PO   | Day 1-5 of a 28 day cycle for 24 additional  cycles           |  
** Temozolomide will not be increased greater than 200 mg/m2/day. No increases in bortezomib above 1.3 mg/kg will be made. Patients will be treated with bortezomib 1.3 mg/m² SQ on days 1, 4, 8, 11, 29, 32, 36, and 39 and temozolomide 75 mg/m²/day during radiation for 42 consecutive days. If there is myelotoxicity (ANC<1.5 or Plt<100) as determined on weekly blood draws, both  
temozolomide and bortezomib will be held until (ANC>1.5 or Plt >100). One dose reduction will be allowed of bortezomib to 1.0 mg/ m² for the duration of the radiation phase. No dose reductions in temozolomide are permitted. If lower dose results in myelotoxicity (ANC<1.5 or Plt <100), treatment will be held until counts have recovered and resumed at this same lower dose. External beam fractionated regional radiation will be given on week days at 200 cGy doses to a total dose of 6000 cGy as specified in Appendix 8.12. The first post-radiation temozolomide cycle should be synchronized to within +/- two days of a bortezomib treatment. After a 2-6 week rest (two weeks preferred, but up to six weeks acceptable depending on toxicity) from temozolomide and bortezomib, following completion of radiation therapy, temozolomide will be restarted at 150 mg/m²/day for 5 days out of every 28. If there is myelotoxicity, dose reduction of both drugs will be planned as in below table. If the initial starting level is tolerated, subsequent cycles will be given at 200mg/m²/day. Bortezomib at 1.3 mg/m² will given on days 1, 4, 8, and 11 of a 28 day cycle commencing on the first day of temozolomide. Temozolomide will not be increased greater than 200 mg/ m²/day. Bortezomib will not be increased greater than 1.3 mg/m²/day. Assuming that the dosages of bortezomib and temozolomide are well tolerated, and no deterioration or treatment related toxicity sufficient to terminate study participation occurs, patients will then undergo clinical and radiographic tumor restaging and continue treatment for 24 additional 28 day cycles. If unacceptable toxicities after the first 12 cycles are observed per investigator's discretion, the bortezomib dosing schedule may be changed to 1.3 mg/m2 weekly for 3 weeks on and 1 week off, with the possibility of further reduction if necessary to 1.3 mg/m2 biweekly.
untitled h1
velcade administration

Bortezomib will be given at 1.3 mg/m² SQ on days 1, 4, 8, 11, 29, 32, 36, and 39 during the 6 weeks of radiation. Bortezomib will be given at 1.3 mg/m² on days 1, 4, 8, and 11 of a 28 day cycle commencing on the first day of temozolomide for up to 24 cycles. Drug will be administered only to eligible patients under the supervision of the investigator or identified sub-investigator(s). Patients may be treated on an out-patient basis, if possible. The drug will be prepared under the supervision of a pharmacist, or appropriately qualified and trained personnel. The amount (in mg) of drug to be administered will be determined based on body surface area. Body surface area is to be calculated based on body weight using a standard nomogram (see section 8.3). The dose should be calculated using patient's baseline weight. If a patient experiences a notable change in weight (loss or gain of 10%) ,
then the patient's dose should be recalculated at that time and will become the new baseline weight. There must be at least 72 hours between each dose of bortezomib.  
INTRAVENOUS AND SUBCUTANEOUS ROUTE OF ADMINISTRATION HAVE DIFFERENT RECONSTITUTED CONCENTRATIONS. CAUTION SHOULD BE USED
WHEN CALCULATING THE VOLUME TO BE ADMINISTERED.
untitled h1
subcutaneous administration

Drug is available in sterile, single use vials containing 3.5 mg of bortezomib. Each vial of bortezomib for Injection should be reconstituted under a laminar flow biological cabinet (hood) within eight hours before dosing with 1.4 mL of normal (0.9%) saline, Sodium  
Chloride Injection USP, so that the reconstituted solution contains bortezomib at a concentration of 2.5 mg/mL for subcutaneous administration.  
Subcutaneous Administration Precautions:
The drug quantity contained in one vial (3.5 mg) may exceed the usual dose required.  
Caution should be used in calculating the dose to prevent overdose.  
When administered subcutaneously, sites for each injection (thigh or abdomen)
should be rotated.  
New injections should be given at least one inch from an old site and never into areas where the site is tender, bruised, erythematous, or indurated.  
If local injection site reactions occur following bortezomib administration subcutaneously, a less concentrated bortezomib solution (1 mg/mL instead of 2.5 mg/mL) may be administered subcutaneously. Alternatively, the IV route of administration should be considered.  
In clinical trials of bortezomib IV, local skin irritation was reported in 5% of patients, but extravasation of bortezomib was not associated with tissue damage. In a clinical trial of subcutaneous VELCADE, a local reaction was reported in 6% of patients as an adverse event, mostly redness.
untitled h1
temozolomide admininstration

Temozolomide will be given at 75 mg/ m²/day during radiation for 42 consecutive days. After a short holiday interval, temozolomide will resume at 150 mg/ m²/day for 5 days out of every 28, and planned to be increased to 200 mg/ m²/day. Temozolomide is rapidly and completely absorbed after oral administration; peak plasma concentrations occur in 1 hour. Food reduces the rate and extent of temozolomide absorption. Mean peak plasma concentration and AUC decreased by 32% and 9%, respectively, and Tmax increased 2-fold (from 1.1 to 2.25 hours) when temozolomide was administered after a modified high-fat breakfast. Therefore, patients will be instructed to take temozolomide on an empty stomach, defined as not eating 1 hour before or 1 hour after drug administration.
untitled h1
3.3.3 dose modification and delay

No dose reductions in temozolomide are allowed during the concomitant phase; however, dose interruptions or discontinuation may occur based on toxicity. The TEMODAR dose should be continued throughout the 42-day concomitant period if all of the following conditions are met: absolute neutrophil count ≥1.5 x 109/L, platelet count ≥100 x109/L,
common toxicity criteria (CTC) non-hematological toxicity no greater then Grade 1 (except for alopecia, nausea, and vomiting), and no greater than Grade 2 for fatigue. During treatment a complete blood count including differential and platelets should be obtained weekly. Temozolomide dosing should be interrupted or discontinued during concomitant phase according to the hematological and non-hematological toxicity criteria as noted in **Table 5**.  
(Note: If temozolomide is interrupted or discontinued, bortezomib will be interrupted or discontinued as well.) PCP prophylaxis is required during the concomitant administration of TEMODAR and radiotherapy, and should be continued in patients who develop lymphocytopenia until recovery from lymphocytopenia (CTC Grade 1).  
| Table 5                                                                                               |                                                                           |                     |
|-------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------|---------------------|
| Temozolomide Dosing interruption or Discontinuation During Concomitant  Radiotherapy and Temozolomide |                                                                           |                     |
| Toxicity                                                                                              | TMZ Interruption a                                                        | TMZ Discontinuation |
| Absolute Neutrophil Count                                                                             | ≥0.5 and <1.5 x 109 /L                                                    | <0.5 x 109 /L       |
| Platelet Count                                                                                        | ≥10 and <100 x 109 /L                                                     | <10 x 109 /L        |
| CTC Non-hematological  toxicity (except for alopecia,  nausea, vomiting, fatigue,  and constipation)  | CTC Grade 3 or intolerable  Grade 2and at the  investigators' discretion. | CTC Grade 4         |
| a  Treatment with concomitant TMZ may be continued when all of the following conditions               |                                                                           |                     |  
a Treatment with concomitant TMZ may be continued when all of the following conditions are met: absolute neutrophil count ≥1.5 x 109/L; platelet count ≥ 100 x 109/L; CTC nonhematological toxicity ≤ Grade 2 (except for alopecia, nausea, vomiting, fatigue, and constipation). TMZ- temozolomide; CTC = Common Toxicity Criteria
untitled h1
bortezomib

If TMZ (and bortezomib) need to be interrupted per criteria in Table 5, resumption of TMZ at 75 mg/ m² and bortezomib at a lower dose (-1 dose reduction) will be allowed when toxicity recovers to an absolute neutrophil count ≥1.5 x 109/L, platelet count ≥100 x109/L, or CTC non-hematologic toxicity ≤ Grade 2 (see Table 5). If counts require TMZ discontinuation, then bortezomib will also be discontinued for the duration of the radiation phase.
untitled h1
radiation phase

| Bortezomib   |                                         |                             |
|--------------|-----------------------------------------|-----------------------------|
| Dose Level   | (days 1, 4, 8, 11, 29, 32,  36, and 39) | Temozolomide (daily x 42 d) |
| -1           | 1.0 mg/m2                               | 75 mg/m2                    |
| Starting     | 1.3 mg/m2                               | 75 mg/m2                    |
untitled h1
maintenance (post-radiation) phase temozolomide and

Dosage of temozolomide in Cycle 1 (maintenance) is 150 mg/ m² once daily for 5 days followed by 23 days without treatment. At the start of Cycle 2, the dose is escalated to 200 mg/ m², if the CTC non-hematologic toxicity for Cycle 1 is Grade 2 (except for alopecia, nausea, vomiting, fatigue, or constipation), absolute neutrophil count (ANC) is ≥1.5 x 109/L, and the platelet count is ≥100 x 109/L. The dose remains at 200 mg/ m² per day for the first 5 days of each subsequent cycle except if toxicity occurs. If the dose was not escalated at Cycle 2, escalation should not be done in subsequent cycles. During treatment, a complete blood count with differential and platelets should be obtained on Day 22 (21 days after the first dose of TEMODAR) or within 72 hours (± 3 days) of that day, and weekly until the ANC is above 1.5 x 109/L (1500/µL) and the platelet count exceeds 100 x 109/L
(100,000/µL).  
The next cycle of TEMODAR should not be started until the ANC and platelet count exceed these levels. Delay in treatment cannot exceed 4 weeks, and tumor must be stable.  Dose reductions during the next cycle should be based on the lowest blood counts and worst nonhematologic toxicity during the previous cycle. Dose reductions or discontinuations during the maintenance phase should be applied according to Tables 6 and 7.  If further dose reductions are required, schedule should follow Table 9.  
Temozolomide and bortezomib dosage will be recalculated during maintenance phase if there is a weight loss or gain of ≥ 10% of baseline weight.  If this is required, then this weight used to recalculate the new dose will then be taken as the new baseline.  
| Table 6                                                                     |                                               |                              |
|-----------------------------------------------------------------------------|-----------------------------------------------|------------------------------|
| Temozolomide Dose Levels for Maintenance Treatment                          |                                               |                              |
| Dose (mg/m²/day)                                                            |                                               |                              |
| Dose Level                                                                  | Remarks                                       |                              |
| –1                                                                          | 100                                           | Reduction for prior toxicity |
| 0                                                                           | 150                                           | Dose during Cycle 1          |
| 200                                                                         | Dose during Cycles 2-6 in absence of toxicity |                              |
| 1                                                                           | Table 7                                       |                              |
| Temozolomide Dose Reduction or Discontinuation During Maintenance Treatment |                                               |                              |
| Toxicity                                                                    | Reduce TMZ by 1 Dose Levela                   | Discontinue TMZ              |
| Absolute Neutrophil Count                                                   | <1.0 x 10 9 / L                               | See footnote b               |
| Platelet Count                                                              | <50 x 10%L                                    | See footnote b               |
| CTC Non-hematological Toxicity                                              |                                               |                              |
| (except for alopecia, nausea, vomiting)                                     | CTC Grade 3                                   | CTC Grade 4b                 |
| ª TMZ dose levels are listed in Table 6.                                    |                                               |                              |  
b TMZ is to be discontinued if dose reduction to <100 mg/m² is required or if the same Grade 3 nonhematological toxicity (except for alopecia, nausea, vomiting) recurs after dose reduction.  
TMZ = temozolomide; CTC = Common Toxicity Criteria.  
  
| Table 9: Maintenance (Post-radiation) (28 day cycle):  Dose Levela Bortezomib Temozolomide (days 1, 4, 8, and 11) (day 1) -3 1.0 mg/m2 75 mg/ m2 -2 1.0 mg/m2 100 mg/ m2 -1 1.3 mg/m2 100 mg/m2 Starting 1.3 mg/m2 150 mg/m2 +1 1.3 mg/m2 200 mg/m2   |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| a Except for neuropathic pain, see Table 3.1 (bortezomib reduced to 0.7 mg/m2 )                                                                                                                                                                       |  
Before each drug dose, the patient will be evaluated for possible toxicities that may have occurred after the previous dose(s). Toxicities are to be assessed according to the NCI Common Terminology Criteria for Adverse Events (CTCAE), Version 3.0 (see section 8.6). All previously established or new toxicities observed any time, with the exception of neuropathic pain and peripheral sensory neuropathy, are to be managed as follows: If the patient experiences febrile neutropenia, a Grade 4 hematologic toxicity (including a platelet count <25  109/L) or any  Grade 3 non-hematologic toxicity considered by the investigator to be related to TMZ or VELCADE, then drugs are to be held. For any ≥ Grade 3 non-hematologic toxicities, VELCADE is to be held for up to 2 weeks until the toxicity returns to Grade 1 or better.  
Dose interruption or study discontinuation is not required for lymphopenia of any grade.  
If, after VELCADE has been held, the toxicity does not resolve, as defined above, then drug must be discontinued. Patients who experience VELCADE-related neuropathic pain and/or peripheral sensory neuropathy are to be managed as presented in Table 3.1 Management of Patients with VELCADE-Related Neuropathic Pain and/or Peripheral Sensory Neuropathy.
untitled h1
table 3-1 management of patients

| Recommended Dose Modification for VELCADE related Neuropathic Pain and/or Peripheral Sensory or Motor  Neuropathy                                                                                                                                                                                                                                          |                                                                                                                                                                                                                                 |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Severity of Peripheral Neuropathy                                                                                                                                                                                                                                                                                                                          | Modification of Dose and Regimen                                                                                                                                                                                                |
| Signs and Symptoms  Grade 1 (paresthesias, weakness and/or loss of                                                                                                                                                                                                                                                                                         | No action                                                                                                                                                                                                                       |
| reflexes) without pain or loss of function  Grade 1 with pain or Grade 2 (interfering with                                                                                                                                                                                                                                                                 | Reduce VELCADE by one dose level* If toxicity                                                                                                                                                                                   |
| function but not with activities of daily living)                                                                                                                                                                                                                                                                                                          | persists reduce by another one dose level. *                                                                                                                                                                                    |
| Grade 2 with pain or Grade 3 (interfering with                                                                                                                                                                                                                                                                                                             | Withhold* VELCADE therapy until                                                                                                                                                                                                 |
| activities of daily living)                                                                                                                                                                                                                                                                                                                                | toxicity resolves.  When toxicity resolves reinitiate with  a reduced dose of VELCADE at 0.7 mg.m2 and  change treatment schedule to once per week.* If  toxicity recurs, change treatment schedule to once  every two weeks. * |
| Grade 4 (Sensory neuropathy which is disabling  or motor neuropathy that is life threatening or  leads to paralysis)                                                                                                                                                                                                                                       | Discontinue VELCADE                                                                                                                                                                                                             |
| Grading based on NCI Common Terminology Criteria CTCAE v3.0  NCI Common Terminology Criteria website - http://ctep.info.nih.gov/reporting/ctc.html  ADL = activities of daily living  *Key:  Reduce by one dose level: VELCADE dose reduction from 1.3 to 1.0, or 1.0 to  0.7mg/m2 /dose. Hold: Interrupt VELCADE until the toxicity returns to Grade 1 or |                                                                                                                                                                                                                                 |  
Hold: Interrupt VELCADE until the toxicity returns to Grade 1 or better.  
Schedule change: Schedule change from VELCADE twice per week (Days 1, 4, 8 and 11 on a Q4W cycle) to once per week (Days 1, 8, and 15 on a Q4W cycle). Change from once per week to once every two weeks (Days 1, 15 on a Q4W cycle).
The neurotoxicity-directed questionnaire (see section 8.8) is a useful tool for determining the presence and intensity of neuropathic pain and/or peripheral neuropathy from the patient's perspective. Neuropathic symptoms are more prominent than abnormalities on the clinical examination. After the patient completes the neurotoxicity-directed questionnaire, the questionnaire should be reviewed to assist with the evaluation of the onset and intensity of peripheral neuropathy and other neurotoxicities that may possibly require intervention or dose modification.  
Patients with mild hepatic impairment (bilirubin ≤ 1.5  ULN) do not require a starting dose adjustment. Please note that patients with bilirubin levels > 1.5 ULN are excluded from enrollment in this protocol. If a patient develops moderate or severe hepatic impairment with bilirubin ≥ Grade 2 (> 1.5 -3.0 X ULN) while on study, the investigator should hold Bortezomib until the toxicity returns to < Grade 2. Restarting Bortezomib at the next lower dosed level could be considered at the Investigator's discretion and following exclusion of Bortezomib-induced liver impairment and careful consideration of liver disease due to other causes, such as, but not limited to, active infection and multiple myeloma-related liver disease. 3.3.4 Treatment Assignment not applicable 3.3.5 Blinding, Packaging, and Labeling VELCADE will be supplied in vials as open-label stock. Both the box label and vial label will fulfill all requirements specified by governing regulations. Temozolomide will be obtained through the patient's pharmacy. 3.3.6 Concomitant Treatment
untitled h1
concurrent therapy

Other Anti-cancer or Experimental Therapy: No other anti-cancer therapy (including chemotherapy, hormonal treatment or immunotherapy) of any kind is permitted during the study period. No other drug under investigation may be used concomitantly with the study drug. Patients are not allowed to participate concurrently in any other clinical study.  
Corticosteroids:Should be used in the smallest dose to control symptoms of cerebral edema and mass effect, and discontinued if possible.  
Anti-seizure medications: Should be used as necessary, however, since VELCADE is partially metabolized by inducers of CYP450 3A4 such as Enzyme-inducing antiepileptic drugs (EIAED), patients on EIAED must be transitioned to non-EAIED at least 2 weeks prior to initiation of treatment.  
Antiemetics: Investigators will use their own discretion with regard to the appropriate treatment of nausea or vomiting.  
Anticoagulants: Patients who require treatment with full-dose warfarin or its equivalent (i.e., unfractionated and/or low molecular weight heparin) will NOT be removed from the study. Frequent monitoring of the INR is recommended.  
Growth Factors: Routine prophylactic use of G-CSF in the first course of therapy is not permitted, and secondary prophylaxis with G-CSF in subsequent courses is not generally recommended. Use of GM-CSF is not permitted at any time. However, prophylactic administration of G-CSF in a patient who is experiencing recurrent difficulties with neutropenia in subsequent cycles, or therapeutic use in patients with serious neutropenic complications such as tissue infection, sepsis syndrome, fungal infection, etc., may be considered at the investigator's discretion.  
Other Concomitant Medications: Therapies considered necessary for the patient's well being may be given at the discretion of the investigator. On the day of VELCADE  
administration, patients should not take any vitamin supplements such as Vitamin C, alpha lipoic acid, any antioxidant, or green tea. Other concomitant medications should be avoided except for analgesics, chronic treatments for concomitant medical conditions, or agents required for life-threatening medical problems. All concomitant medications (prescription and OTC) must be recorded in the medical record and the case report forms.  
Potential drug interactions: Bortezomib has the ability to inhibit a variety of liver metabolic enzymes in vitro. The clinical impact of this inhibition in human taking drugs metabolized by these enzymes is unknown. Therefore, all patients enrolled onto this trial who are taking concomitant medications that are known to be metabolized by the liver should be closely observed for side-effects of these concomitant medications. (see Appendix 8.13 for the list of those medications)
Febrile neutropenia: May be managed according to the local institution's Infectious Disease guidelines. Measures may include appropriate laboratory testing, including blood and urine cultures, and the institution of broad-spectrum antibiotics. If a source for the fever is not identified, or the fever resolves when the neutrophil count recovers, antibiotics may be discontinued and the patient observed.  
Pneumocystis Pneumonia (PCP) prophylaxis:
Since patients with malignant gliomas are at increased risk of developing PCP, especially if they are on corticosteroids, prophylaxis for PCP may be considered per institutional practice.  
Any investigational agent other than VELCADE is not permitted.
untitled h1
3.3.7 treatment compliance

All drug will be administered to eligible patients under the supervision of the investigator or identified sub-investigator(s). The pharmacist will maintain records of drug receipt (if applicable), drug preparation, and dispensing, including the applicable lot numbers, patients' height, body weight, and body surface area (see section 8.3), and total drug administered in milliliters and milligrams. Any discrepancy between the calculated dose and dose administered, and the reason for the discrepancy, must be recorded in the source documents.
untitled h1
3.4 duration of treatment and

Patients will receive up to 24 28 day cycles of temozolomide and bortezomib after radiation therapy. All patients will be followed for survival. Patients who progress will be followed for survival every 4 months. Patients who complete therapy and do not progress should be followed every 2 months for 12 months, every 3 months for the next 12 months, every 4 months for the next 12 months, and then every 6 months until progression is determined. They should then be followed for survival every 4 months. Patients taken off study because of unacceptable toxicities will be followed up every 2 months until the toxicity is resolved or progression is determined by MRI.
untitled h1
3.5 termination of treatment and/or

Patients will be informed that they have the right to withdraw from the study at any time for any reason, without prejudice to their medical care. The investigator also has the right to withdraw patients from the study for any of the following reasons:
Intercurrent illness  
Occurrence of an unacceptable adverse event A treatment cycle delay or VELCADE and TMZ interruption of >4 weeks or missing three of four VELCADE doses within a treatment cycle because of toxicity Patient request Protocol violations Non-compliance Administrative reasons Failure to return for follow-up General or specific changes in the patient's condition unacceptable for further treatment in the judgment of the investigator Progressive disease at any time
At the time of withdrawal, patients must have a physical exam, a neurological exam, urine tests and routine blood tests. The primary reason for a patient's withdrawal from the study is to be recorded in the source documents.
untitled h1
3.6 efficacy pharmacodynamic/pharmacogenomic/correlative studies and

3.6.1 Efficacy Measurements 3.6.1.1 Primary Efficacy Variables: Overall Survival
3.6.1.2 Secondary Efficacy Variables: 12-month survival and median time to tumor progression tumor response as assessed by MRI and neurologic exam, toxicity. The patients will have a brain MRI evaluation of response and progression every 8 weeks, starting from the day 56 scan obtained 2 weeks after completion of radiation and daily temozolomide. MRI assessment will be conducted on a 7-point scale. This scale is expected to be more useful in this study because many newly-diagnosed patients are likely not to have evaluable disease due to gross total resections. A -2 or - 3 assessment will be taken as progression. Determination of whether progression occurs based on the day 56 scan will take into account the untreated window between baseline MRI and day of 1 of the study. complete resolution of tumor: 3 tumor definitely smaller: 2 tumor probably smaller: 1 tumor unchanged: 0 tumor probably worse: -1 tumor definitely worse: -2 new lesion: -3 Neurological Exam: Although not used for determining response, it is useful to evaluate improvement in the neurologic exam that should coincide with objective measurement of tumor size.  
+2 Definitely better +1 Possibly better  
0 Unchanged  
-1 Possibly worse  
-2 Definitely worse  
B Baseline  
Performance Status, Neurological Function, and Mental Status: Patients will be graded according to Karnofsky Performance Status (see Appendix 8.2),
Neurological Function and Mental Status.  
Time to Treatment Failure: From date of registration to the date of first observation of progressive disease, non-reversible neurologic progression, or permanently increased steroid requirement (applies to stable disease only), death due to any cause, or early discontinuation of treatment.
Time to Death: From date of registration to date of death due to any cause. Molecular Analysis: Pre-treatment biomarker data (MGMT promoter methylation and IDH1 genotype) will be analyzed and descriptive statistics will be generated. Analyses of a graphical nature comparing the biomarker data with the best overall response (CR, PR, SD, PD) are also planned.  
3.6.2 Pharmacokinetic/Pharmacodynamic/Pharmacogenomic/Correlative Studies  
  
3.6.3 Safety Measurements Toxicity/safety: Patients will be assessed using CTC 3.0 for Grade 3 or greater treatment related non-hematologic toxicities.
untitled h1
4 adverse events

All serious adverse events (SAEs) (regardless of expectedness, causality, and whether commercial or investigational bortezomib is used) must be reported to Millennium Pharmacovigilance (or designee). See Section 4.2 for the reporting of SAEs. The sponsor-investigator is responsible to meet all regulations and requirements applicable to the sponsor-investigator.
untitled h1
4.1 definitions 4.1.1 adverse event

CONFIDENTIAL Page 52 of 86 Amendment 7 version dated February 11, 2014  
  
Adverse event (AE) means any untoward medical occurrence in a patient or subject administered a pharmaceutical product; the untoward medical occurrence does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product whether or not it is related to the medicinal product. This includes any newly occurring event, or a previous condition that has increased in severity or frequency since the administration of study drug.  
For this protocol an abnormal laboratory value will not be assessed as an AE unless that value leads to discontinuation or delay in treatment, dose modification, therapeutic intervention, or is considered by the investigator to be a clinically significant change from baseline.  
4.1.2 Serious Adverse Event Definition Serious adverse event (SAE) means any untoward medical occurrence that at any dose:
Results in **death**.  
Is **life-threatening**. (refers to an AE in which the patient was at risk of death at the time of the event. It does not refer to an event which hypothetically might have caused death if it were more severe).
Requires inpatient **hospitalization or prolongation of existing hospitalization**.  
(see clarification below on planned hospitalizations in Section **Error! Reference** source not found.).  
Results in **persistent or significant disability/incapacity**. Disability is defined as a substantial disruption of a persons' ability to conduct normal life functions.  
Is a congenital anomaly/birth defect. Is a medically important event. This refers to an AE that may not result in death, be immediately life threatening, or require hospitalization, but may be considered serious when, based on appropriate medical judgment, may jeopardize the patient, require medical or surgical intervention to prevent 1 of the outcomes listed above, or involves suspected transmission via a medicinal product of an infectious agent. Examples of such medical events include allergic bronchospasm requiring intensive treatment in an emergency room or at home, blood dyscrasias or convulsions that do not result in inpatient hospitalization, or the development of drug dependency or drug abuse; any organism, virus, or infectious particle (eg, prion protein transmitting Transmissible Spongiform Encephalopathy), pathogenic or nonpathogenic, is considered an infectious agent.  
Clarification should be made between a serious AE (SAE) and an AE that is considered severe in intensity (Grade 3 or 4), because the terms serious and severe are NOT synonymous. The general term severe is often used to describe the intensity (severity) of a specific event; the event itself, however, may be of relatively minor medical significance (such as a Grade 3 headache). This is NOT the same as serious, which is based on patient/event outcome or action criteria described above, and is usually associated with events that pose a threat to a patient's life or ability to function. A severe AE (Grade 3 or 4) does not necessarily need to be considered serious. For example, a white blood cell count of 1000/mm3 to less than 2000 is considered Grade 3 (severe) but may not be considered serious. Seriousness (not intensity) serves as a guide for defining regulatory reporting obligations.
untitled h1
4.2 procedures for ae and

AEs may be spontaneously reported by the patient and/or in response to an open question from study personnel or revealed by observation, physical examination, or other diagnostic procedures. Any clinically relevant deterioration in laboratory assessments or other clinical finding is considered an AE. When possible, signs and symptoms indicating a common  
underlying pathology should be noted as one comprehensive event. AEs which are serious must be reported to Millennium Pharmacovigilance (or designee) from the first dose of bortezomib up to and including 30 days after administration of the last dost of bortezomib. Any SAE that occurs at any time after completion of bortezomib treatment or after the designated follow-up period that the sponsor-investigator and/or sub-investigator considers to be related to any study drug must be reported to Millennium Pharmacovigilance (or designee). Planned hospital admissions or surgical procedures for an illness or disease that existed before the patient was enrolled in the trial are not to be considered AEs unless the condition deteriorated in an unexpected manner during the trial (e.g., surgery was performed earlier or later than planned). All SAEs should be monitored until they are resolved or are clearly determined to be due to a patient's stable or chronic condition or intercurrent illness(es). Since this is an investigator-initiated study, the principal investigator , also referred to as the sponsor-investigator, is responsible for reporting serious adverse events (SAEs) to any regulatory agency and to the sponsor- investigator's EC or IRB. Regardless of expectedness or causality, all SAEs (including serious pretreatment events) must also be reported to Millennium Pharmacovigilance. Fatal and Life Threatening SAEs within 24 hours but no later than 4 calendar days of the sponsor-investigator's observation or awareness of the event All other serious (non-fatal/non life threatening) events within 4 calendar days of the sponsor-investigator's observation or awareness of the event The protocol may include language to specify expected adverse events which will not be considered serious and will not require expedited reporting. See below for contact information for the reporting of SAEs to Millennium Pharmacovigilance.  
The sponsor-investigator must fax the SAE Form per the timelines above. A sample of an SAE Form will be provided. The SAE report must include at minimum:  
Event term(s) Serious criteria Intensity of the event(s): Sponsor-investigator's or sub-investigator's determination. Intensity for each SAE, including any lab abnormalities, will be determined by using the NCI CTCAE version specified in the protocol, as a guideline, whenever possible. The criteria are available online at
http://ctep.cancer.gov/reporting/ctc.html.  
Causality of the event(s): Sponsor-investigator's or sub-investigator's determination of the relationship of the event(s) to study drug administration.
Follow-up information on the SAE may be requested by Millennium. Intensity for each SAE, including any lab abnormalities, will be determined by using the NCI CTCAE version used at your institution, as a guideline, whenever possible. The criteria are available online at http://ctep.cancer.gov/reporting/ctc.html. In the event that this is a multisite study, the sponsor-investigator is responsible to ensure that the SAE reports are sent to Millennium Pharmacovigilance (or designee) from all sites participating in the study. Sub-investigators must report all SAEs to the sponsor-investigator so that the sponsor-investigator can meet his/her foregoing reporting obligations to the required regulatory agencies and to Millennium Pharmacovigilance, unless otherwise agreed between the sponsor-investigator and sub-investigator(s).  
Relationship to all study drugs for each SAE will be determined by the investigator or subinvestigator by responding yes or no to the question: Is there a reasonable possibility that the AE is associated with the study drug(s)? Sponsor-investigator must also provide Millennium Pharmacovigilance with a copy of all communications with applicable regulatory authorities related to the study products as soon as possible but no later than 4 calendar days of such communication.  
  
Suggested Reporting Form:
SAE Report Form (a sample is provided in Appendix **Error! Reference source not**
found.)
US FDA MedWatch 3500A:
http://www.fda.gov/Safety/MedWatch/HowToReport/DownloadForms/default.htm Any other form deemed appropriate by the sponsor-investigator
untitled h1
4.3 procedures for reporting drug

If a woman becomes pregnant or suspects that she is pregnant while participating in this study, she must inform the investigator immediately and permanently discontinue study drug. The sponsor-investigator must fax a completed Pregnancy Form to the Millennium Department of Pharmacovigilance or designee (see Section 4.2). The pregnancy must be followed for the final pregnancy outcome. If a female partner of a male patient becomes pregnant during the male patient's participation in this study, the sponsor-investigator must also immediately fax a completed Pregnancy Form to the Millennium Department of Pharmacovigilance or designee (see Section 4.2). Every effort should be made to follow the pregnancy for the final pregnancy outcome. Suggested Pregnancy Reporting Form: Pregnancy Report Form (Appendix 8.15)
untitled h1
5 statistical procedures 5.1 sample

The sample size calculation for this one-arm trial is based on an endpoint of 18-month survival rate with a 36-month accrual period (1-2 patients/month). The following assumptions are made: 1. Survival time follows an exponential distribution, 2. The 18-month survival rate is 55% (median survival 21 months) for the new treatment and 40% (median survival 14 months) for the standard treatment (based on (Stupp, Mason et al. 2005), 3. The 18-month survival rate is estimated using the Kaplan-Meier method, 4. Test statistics - Z-test, Type I error=0.05, 5. N=50 (total patients). In a performed simulation, the power is 70% for 1-sided test.
untitled h1
5.2 randomization and stratification not

5.3 **Populations for Analysis**
This study will be a multi-center, open-label, phase II study assessing safety and efficacy in adult newly-diagnosed GBM patients that have had no prior therapy other than surgery. This study was designed to include women and minorities, but was not designed to measure differences of intervention effects. Males and females will be recruited with no preference to gender. No exclusion to this study will be based on race. Minorities will actively be recruited to participate.
untitled h1
5.4 procedures for handling missing

All data will be stored in the patient's medical record and duplicates or research specific CRFs in their research records. We will only be collecting data that is relevant for this study. All unused data will be stored per medical records policy and procedures for handling of medical records.
untitled h1
5.5 statistical methods 5.5.1 baseline

The primary endpoint will be total survival from the date of surgical-pathological diagnosis. For the final analysis, results will be compared with the results on comparable patients whose data are available through the UCLA Neuro-oncology Department database. These comparable patients were all newly diagnosed GBM patients who were treated on research protocols and similar to the patients in the present study insofar as they will be patients seen at a tertiary center and enrolled into clinical trials early after diagnosis. The primary analysis will utilize a Cox proportional hazards model including age, KPS, and extent of resection. This allows for adjustment for major prognostic factors.
untitled h1
5.5.2 efficacy analysis primary efficacy

12-month survival and median time to tumor progression tumor response as assessed by MRI and neurologic exam, toxicity.  
The patients will have a brain MRI evaluation of response and progression every 8 weeks, starting from the day 56 scan obtained 2 weeks after completion of radiation and daily temozolomide. Assessment will be conducted on a 7-point scale. This scale is expected to be more useful in this study because many newly-diagnosed patients are likely not to have evaluable disease due to gross total resections. A -2 or -3 assessment will be taken as progression. Determination of whether progression occurs based on the day 56 scan will take into account the untreated window between baseline MRI and day of 1 of the study. complete resolution of tumor: 3 tumor definitely smaller: 2 tumor probably smaller: 1 tumor unchanged: 0 tumor probably worse: -1 tumor definitely worse: -2 new lesion: -3 Neurological Exam: Although not used for determining response, it is useful to evaluate improvement in the neurologic exam that should coincide with objective measurement of tumor size.  
+2 Definitely better +1 Possibly better 0 Unchanged
-1 Possibly worse -2 Definitely worse B Baseline Performance Status, Neurological Function, and Mental Status: Patients will be graded according to Karnofsky Performance Status, Neurological Function and Mental Status (see Appendix 8.2).  
Time to Treatment Failure: From date of registration to the date of first observation of progressive disease, non-reversible neurologic progression or permanently increased steroid requirement (applies to stable disease only), death due to any cause, or early discontinuation of treatment.
Time to Death: From date of registration to date of death due to any cause. Molecular Analysis: Pre-treatment biomarker data (MGMT and IDH1) and additional correlative markers will be analyzed and descriptive statistics will be generated. Exploratory analyses of a graphical nature comparing the biomarker data with the best overall response (CR, PR, SD, PD) are also planned.  
5.5.3 Safety Analysis The PI will be responsible for accurate, consistent, timely, complete, and reliable data collection. The study coordinator and PI are responsible for ensuring that the following forms are completed in a legible and timely manner for every patient enrolled on study. These forms are an integral part of the study data and will be maintained in the patient's clinical chart at UCLA. Errors on the forms should be lined through, but not obliterated with the correction inserted, initialed and dated by the study coordinator or PI. These forms will be available at all times for inspection by the FDA and UCLA. Registration Form On-study Eligibility Checklist UCLA Adverse Event Form MedWatch Form (Form 3500)
In addition to the patient data maintained on the forms listed above, patient data will also be entered into a Microsoft Excel spreadsheet or database. The data are backed up daily and stored on a secure medical center server. The PI, study investigators and data coordinator for the study are the only individuals who will have access to the password-protected data file. Quality assurance measures are provided by three mechanisms: 1) ongoing monitoring of protocol compliance, 2) on-site audits, and 3) response reviews. Monitoring will begin at the time of patient registration and will continue during protocol performance and completion. This trial is subject to Cancer Center Internal Quality Assurance Monitoring. Data and the progress of this trial will be reported to the DSMB at regular intervals as determined by the DSMB. The first data summary report will be due quarterly, starting from the date of the IRB approval.
untitled h1
jccc dsmb

This trial is subject to the Jonsson Comprehensive Cancer Center Internal Quality Assurance program. The JCCC Data and Safety Monitoring Board (DSMB) meets monthly to review all serious adverse event reports for trials overseen by the JCCC DSMB. All serious adverse event (SAE) reports, which have been filed since the previous meeting, are presented to the committee for review. For all trials where the JCCC DSMB has primary oversight for SAE review, all SAEs occurring within these studies shall be reported to the JCCC DSMB in a timely manner consistent with the UCLA IRB time requirements [ten days, two days for a death] regardless of relationship, expectedness or severity. The JCCC Office of Regulatory Compliance (ORC) will review all submissions and the ORC staff will enter the information into the JCCC Clinical Trials database. Reports are generated for full JCCC DSMB review of those SAEs that have some component of relatedness to the study drug and may, at the discretion of the JCCC compliance officers, include SAE reports that may require DSMB review. For trials where the JCCC DSMB has primary DSMB review responsibility, the DSMB will  
request that the PI generate cumulative adverse event reports for quarterly, biannual or annual review.  
The DSMB reviews each SAE report and determines whether or not protocol modifications are warranted to ensure subject safety. In this review, prior occurrences of similar toxicity with the therapy under study are taken into consideration, as well as the servity of the event and the likelihood that it was related to a study drug. The DSMB may recommend no changes to the study if the event is expected or related to other causes such as the subject's underlying condition. The DSMB may request an expert's advice of another non-Principal Investigator with national experience to support their deliberations and decisions. The JCCC DSMB has the authority to recommend to the UCLA IRB the immediate halt to the study (i.e., discontinuation of any further treatment of enrolled subjects and discontinuation of enrollment of new subjects) should there be any serious unexpected toxicity that warrants further investigation. JCCC DSMB correspondences are addressed to the Principal Investigator and copied to the UCLA IRB. Minutes of the DSMB meetings are recorded and processed into the computer file.
untitled h1
monitoring auditing and reporting

The NIH and NCI policy statements allow for variable monitoring and reporting plans, commensurate with the potential risks and with the size and complexity of the trial. The monitoring plan must be sufficiently rigorous and effective to ensure subject safely and to ensure protocol compliance and data validity and integrity. Level of Risk of a Study All interventional clinical trials undergo scientific review by the Internal Scientific Peer Review Committee (ISPRC) which requires that a Data and Safety Monitoring Plan is in place before a trial can be approved to begin. For trials overseen by the JCCC DSMB, the JCCC DSMB will determine the degree of risk of the study and will ensure that there are procedures in place to ensure the safety of the subjects that are enrolled in the trial. The intensity level of the monitoring is determined by the risk category. Some of the factors that must be considered when assigning the Level of Risk category include:  
1. A biostatistical design and appropriate procedures for proper data management so that the information collected can be properly validated.  
2. Appropriate Serious Adverse Event reporting procedures must be in place. 3. The study duration must be appropriate and must be based on a realistic rate of enrollment.  
4. Data collection and data management must be adequate to verify and ensure subject eligibility.
untitled h1
assignment of risk

Assigning risk ensures that the data and safety monitoring is based on the level of risk (low, medium, or high) to ensure that the data and safety monitoring activities are appropriate. Below are some of the criteria used to make a decision regarding the assignment of risk:
Expected duration of the study based upon the estimated rate of enrollment.  
Type of study population (e.g., children, geriatric)
The procedures used in the trial are commensurate with the degree of risk. Adequate data management systems in place and appropriate case report forms  
Proper serious adverse event reporting procedures in place Proper biostatistical design and data analysis procedures in place.
untitled h1
level of risk level 2

Example of type of trial: Institutional study for which IND is exempt by FDA. Examples are studies using commercially available agents for an unapproved indication based on standard regimen.  
1. Compliance Officer meets with PI/Staff prior to study initiation; review regulatory requirements and operating system. Compliance Officer provides real time monitoring to determine eligibility prior to enrollment onto the protocol.  
2. Real time QA monitoring of the subjects and data collection occurs for all subjects entered onto the trial.  
3. Comprehensive QA auditing within first year or first 10 subjects enrolled, whichever comes first. Subsequent audit frequency will be annually.  
4. Frequency of DSMB Summary Report is typically on a biannual basis or approximately every six months.
untitled h1
monitoring and auditing activities

The compliance officer of the JCCC Office of Regulatory Compliance [ORC] will monitor the clinical records for all human subjects enrolled onto JCCC trials overseen by the JCCC DSMB. The JCCC compliance officer will perform real time review of informed consent processes and the meeting of all inclusion and exclusion criteria and screening results at study entry. Active monitoring will offer the JCCC study teams prospective information that can be used to enhance the quality of research being performed contemporaneously. Auditing is a review of historic performance of the research effort and is performed on case report forms, regulatory files and source documents to measure the quality of the research effort in a retrospective manner. This study will be conducted at UCLA Medical Center and Columbia University Medical Center. The study will be monitored by the UCLA JCCC Quality Assurance Program and they may perform audits of the Columbia University Medical Center if deemed necessary. In addition, a monthly team conference will be done among study investigators from all external network study sites during which toxicity data including all SAEs will be reviewed and other issues relevant to the study such as interim assessment of accrual, outcome and compliance with study guidelines. The PI will be responsible for ensuring that study monitoring requirements are met. Upon request the monthly safety meeting agenda will be submitted also to the UCLA JCCC Quality Assurance Program. The quality control procedure of data and protocol adherence will be performed through a site visit and/or teleconference at external network study sites by the study coordination center personnel from the UCLA Neuro-Oncology Center at least once a year. Copies of all monitoring and audit reports at external study sites will be provided to UCLA JCCC DSMB. 5.5.4 For this multi-center clinical trial, the following organizations are involved in the  
  
All clinical sites are responsible for the recruitment, treatment, and evaluation of patients with newly diagnosed brain tumor who meet eligibility criteria. Each site will include one or more responsible physicians/ investigators, and a study coordinator. The investigator and coordinator from the study coordination center, UCLA Neuro-Oncology Program, who represents the institution, will provide oversight of the following procedures at external network study sites including eligibility verification.  
- Eligibility Screening: FAX a copy of the eligibility checklist form and registration form to review and verification of eligibility. No exemption will be granted for any study entry at external network sites without prior approval by the PI.  
- Clinical evaluation: all data will be captured and recorded on the case report forms provided. The quality control procedure of data and protocol adherence will be performed through a site visit to each network site by study coordination center personnel from UCLA Neuro-Oncology Center. Study oversight will begin at the time of subject registration and will continue during protocol performance and completion. Monthly safety meeting will take place in order to review of currently enrolled patients at each site.  
- Data Management: updating and maintenance of case report forms and subjects files, solving the data queries, updating and maintenance of subject's status log, reporting all SAEs occurring at sites.  
a) The above referenced study will have an externally constituted safety monitoring group. In addition, external sites have their own DSMB plans.  
b) Safety data is reviewed on a continual basis as adverse events and reports of toxicities, laboratory findings and reports of Serious Adverse Events are received.  
c) Serious adverse events are reported to the main coordination center using
specific forms provided to the sites.  Upon receipt of a report, the Medical Monitor will review the event or toxicity and forward the information with comments or recommendations to the Principal Investigator at each site. Documents consists of a cover letter and corresponding safety report(s) will be sent via e-mail attachments within five working days from the date the documents.  
If required, the Medical Monitor from U
will confer with the Principal Investigator at the site reporting the event to determine a course of action regarding patient treatment, dose modification or suspension of patient treatment.  Main coordination center will report to the FDA, a narrative will be prepared by the Medical Monitor and forward all MedWatch Form FDA 3500A to the participating sites, and the manufacturer of the study drug, Millennium Pharmaceuticals, Inc.  
d) Safety assessments will consist of monitoring and recording protocoldefined adverse events (AEs) and Serious Adverse Events (SAEs);
measurement of protocol-specified tumor progression, laboratory results, clinical examination; and other protocol-specified tests that are deemed critical to the safety evaluation of the study drug. All study-related safety data will be collected until 30 days after the last dose of study drugs.  
Survival status will be collected every 4 months until death.  
5.5.5  Correlative studies
untitled h1
interim analysis

After 10 patients with newly-diagnosed GBM are treated, an interim analysis will be conducted.  If 3 or more patients have experienced unacceptable toxicity (defined as grade 4 non-hematologic toxicity or any grade 5), enrollment will be suspended pending full assessment of safety risks to determine if the study should continue.  
Otherwise, patient accrual will continue.  
Procedures for Reporting Deviations to Original Statistical Analysis Plan All deviations will be reported to our local IRB as they occur and on an annual basis per standard procedures for reporting.
untitled h1
6 administrative requirements 6.1 product

A product complaint is a verbal, written, or electronic expression which implies dissatisfaction regarding the identity, strength, purity, quality, or stability of a drug product. Individuals who identify a potential product complaint situation should immediately contact MedComm Solutions (see the following) and report the event. Whenever possible, the associated product should be maintained in accordance with the label instructions pending further guidance from a Millennium quality representative. A medication error is a preventable event that involves an identifiable patient and that leads to inappropriate medication use, which may result in patient harm. While overdoses and underdoses constitute medication errors, doses missed inadvertently by a patient do not. Individuals who identify a potential medication error situation should immediately contact MedComm Solutions (see below) and report the event. Product complaints and medication errors in and of themselves are not AEs. If a  
 product complaint or medication error results in an SAE, an SAE form should be completed and sent to PPD (refer to Section 4.2).
untitled h1
7 references

Amiri, K. I., L. W. Horton, et al. (2004). "Augmenting Chemosensitivity of Malignant Melanoma Tumors via Proteasome Inhibition: Implication for Bortezomib (VELCADE, PS-341) as a Therapeutic Agent for Malignant Melanoma." Cancer Res %R 10.1158/0008-5472.CAN-04067364(14): 4912-4918.  
Berges, O., D. Decaudin, et al. (2008). "Concurrent radiation therapy and bortezomib in myeloma patient." Radiother Oncol86(2): 290-2.  
Bredel, M., C. Bredel, et al. (2006). "Tumor necrosis factor-alpha-induced protein 3 as a putative regulator of nuclear factor-kappaB-mediated resistance to O6-alkylating agents in human glioblastomas."J Clin Oncol24(2): 274-87.  
Bredel M, Scholtens DM, Yadav AK, et al. NFKBIA Deletion in Glioblastomas. New Engl J
Med.2011;364(7):627-637.  
Butowski, N., M. D. Prados, et al. (2005). "A phase II study of concurrent temozolomide and cisretinoic acid with radiation for adult patients with newly diagnosed supratentorial glioblastoma."Int J Radiat Oncol Biol Phys61(5): 1454-9.  
Davies, A. M., P. N. Lara, Jr., et al. (2007). "Incorporating Bortezomib into the Treatment of Lung Cancer." Clin Cancer Res %R 10.1158/1078-0432.CCR-07-033413(15): 4647s-4651.  
Edelman, M. J. (2005). "The potential role of bortezomib in combination with chemotherapy and radiation in non-small-cell lung cancer." Clin Lung Cancer**7 Suppl 2**: S64-6.  
Kubicek, G. J., M. Werner-Wasik, et al. (2008). "Phase I Trial Using Proteasome Inhibitor Bortezomib and Concurrent Temozolomide and Radiotherapy for Central Nervous System Malignancies." Int J Radiat Oncol Biol Phys.  
Lai, A., E. Filka, et al. (2008). "Phase II Pilot Study of Bevacizumab in Combination With Temozolomide and Regional Radiation Therapy for Up-Front Treatment of Patients With Newly Diagnosed Glioblastoma Multiforme: Interim Analysis of Safety and Tolerability." Int J Radiat Oncol Biol Phys.  
Orlowski, R. Z. and D. J. Kuhn (2008). "Proteasome Inhibitors in Cancer Therapy: Lessons from the First Decade." Clin Cancer Res %R 10.1158/1078-0432.CCR-07-221814(6): 1649-1657.  
Raychaudhuri, B., Y. Han, et al. (2007). "Aberrant constitutive activation of nuclear factor kappaB in glioblastoma multiforme drives invasive phenotype." J Neurooncol85(1): 39-47.  
Robins, H. I., M. Won, et al. (2006). "Phase 2 trial of radiation plus high-dose tamoxifen for glioblastoma multiforme: RTOG protocol BR-0021 10.1215/S1522851705000311." Neuro-oncol8(1): 47-52.  
Russo, S. M., J. E. Tepper, et al. (2001). "Enhancement of radiosensitivity by proteasome inhibition:
implications for a role of NF-kappaB." Int J Radiat Oncol Biol Phys50(1): 183-93.  
Stupp, R., W. P. Mason, et al. (2005). "Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma." N Engl J Med352(10): 987-96.  
Styczynski, J., D. Olszewska-Slonina, et al. (2006). "Activity of bortezomib in glioblastoma."
Anticancer Res26(6B): 4499-503.  
Van Waes, C., A. A. Chang, et al. (2005). "Inhibition of nuclear factor-kappaB and target genes during combined therapy with proteasome inhibitor bortezomib and reirradiation in patients with recurrent head-and-neck squamous cell carcinoma." Int J Radiat Oncol Biol Phys63(5):
1400-12.  
Wrensch, M., Y. Minn, et al. (2002). "Epidemiology of primary brain tumors: current concepts and review of the literature." Neuro-oncol4(4): 278-99.  
Yamini, B., X. Yu, et al. (2007). "Inhibition of nuclear factor-kappaB activity by temozolomide involves O6-methylguanine induced inhibition of p65 DNA binding." Cancer Res67(14):
6889-98.  
Yin, D., H. Zhou, et al. (2005). "Proteasome inhibitor PS-341 causes cell growth arrest and apoptosis in human glioblastoma multiforme (GBM)." Oncogene24(3): 344-54.
untitled h1
velcade references

Adams J, Palombella VJ, Sausville EA, Johnson J, Destree A, Lazarus DD et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 1999; 59 (11):2615-22.  
Blade J, Samson D, Reece D, Apperley J, Bjorkstrand B, Gahrton G et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 1998; 102 (5):1115-23.  
Cusack JC, Jr., Liu R, Houston M, Abendroth K, Elliott PJ, Adams J et al. Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition. Cancer Res 2001; 61 (9):3535-40.  
Fossella FV, DeVore R, Kerr RN, Crawford J, Natale RR, Dunphy F et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced nonsmall-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol 2000; 18 (12):2354-62.  
Fossella F. Docetaxel + Cisplatin (DC) and Docetaxel + Carboplatin (DCb) vs Vinorelbine +
Cisplatin (VC) in chemotherapy-naïve patients with advanced and metastatic non-small cell lung cancer (NSCLC): Results of a multicenter, randomized phase III study. European Journal of Cancer, European Cancer Conference, ECCO 11, 2001; Lisbon, Portugal. 37(suppl 6):S154. Abstract 562 Hideshima T, Richardson P, Chauhan D, Palombella VJ, Elliott PJ, Adams J et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 2001; 61 (7):3071-6.  
Jagannath S, Barlogie B, Berenson J et al. A Phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol 2004: 127:165-172 LeBlanc R, Catley LP, Hideshima T, Lentzsch S, Mitsiades CS, Mitsiades N et al.  
Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res 2002; 62 (17):4996-5000.  
Lightcap ES, McCormack TA, Pien CS, Chau V, Adams J, Elliott PJ. Proteasome inhibition measurements: clinical application. Clin Chem 2000; 46 (5):673-83.  
McConkey DJ, Pettaway C, Elliott P, Adam J, Papandreou C, Herrmann JL et al. The proteasome as a new drug target in metastatic prostate cancer. 7th Annual Genitourinary Oncology Conference, 1999; Houston, TX. Abstract Orlowski RZ, Stinchcombe TE, Mitchell BS, Shea TC, Baldwin AS, Stahl S et al. Phase I
Trial of the Proteasome Inhibitor PS-341 in Patients with Refractory Hematologic Malignancies. J Clin Oncol 2002; 20 (22):4420-7.  
Papandreou C, Daliani D, Millikan RE, Tu S, Pagliaro L, Adam J. Phase I Study of Intravenous (I.V.) Proteasome Inhibitor PS-341 in Patients (Pts) with Advanced Malignancies. Proc Am Soc Clin Oncol, 2001. Abstract 340 Pink MM, Pien CS, Ona VO, Worland P, Adams J, Kauffman MG. PS-341 enhances chemotherapeutic effect in human xenograft models. Proc Am Assoc Cancer Res, 2002; San Francisco, CA. Abstract 787  
Richardson PG, Barlogie B, Berenson J et al. A Phase II study of Bortezomib in Relapsed, Refractory Myeloma. N Engl J Med 2003; 348:2609-2617 Richardson PG, et al., Bortezomib or High-Dose Dexamethasone for Relapsed Multiple Myeloma. N Engl J Med 2005; 352:2487-98.  
Richardson et al, Bortezomib Continues to Demonstrate Superior Efficacy Compared With High-Dose Dexamethasone in Relapsed Multiple Myeloma: Updated Results of the APEX Trial. Blood, 2005; 106: Abstract 2547.  
Steiner P, Neumeier H, Lightcap E, Sadis S, Pien C, Pink M et al. Adaptation of Human Tumor Cell Lines to PS-341. AACR-NCI-EORTC International Conference, 2001; Miami Beach, FL. Millennium Pharmaceuticals, Inc., 75 Sidney Street, Cambridge, MA 02139. Abstract Teicher BA, Ara G, Herbst R, Palombella VJ, Adams J. The proteasome inhibitor PS-341 in cancer therapy. Clin Cancer Res 1999; 5 (9):2638-45.  
VELCADE (bortezomib) [package insert]. Cambridge, MA: Millennium Pharmaceuticals, Inc.; 2003.  
1 Adams J, Palombella VJ, Sausville EA, Johnson J, Destree A, Lazarus DD, et al.  
Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 1999;59(11):2615-22.  
2Teicher BA, Ara G, Herbst R, Palombella VJ, Adams J. The proteasome inhibitor PS341 in cancer therapy. Clin Cancer Res 1999;5(9):2638-45.  
3 Cusack JC, Jr., Liu R, Houston M, Abendroth K, Elliott PJ, Adams J, et al. Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition. Cancer Res 2001;61(9):3535-40.  
4LeBlanc R, Catley LP, Hideshima T, Lentzsch S, Mitsiades CS, Mitsiades N, et al.  
Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res 2002;62(17):4996-5000.  
5 Williams S, Pettaway C, Song R, Papandreou C, Logothetis C, McConkey DJ.  
Differential effects of the proteasome inhibitor bortezomib on apoptosis and angiogenesis in human prostate tumor xenografts. Mol Cancer Ther 2003;2(9):835-43.  
6 Nawrocki ST, Bruns CJ, Harbison MT, Bold RJ, Gotsch BS, Abbruzzese JL, et al.  
Effects of the proteasome inhibitor PS-341 on apoptosis and angiogenesis in orthotopic human pancreatic tumor xenografts. Mol Cancer Ther 2002;1(14):1243-53.  
7Satou Y, Nosaka K, Koya Y, Yasunaga JI, Toyokuni S, Matsuoka M. Proteasome inhibitor, bortezomib, potently inhibits the growth of adult T-cell leukemia cells both in vivo and in vitro. Leukemia 2004;18:1357-63.  
8 Boccadoro M, Morgan G, Cavenagh J. Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy. Cancer Cell Int 2005;5:18.  
9 Goel A, Dispenzieri A, Geyer SM, Greiner S, Peng KW, Russell SJ. Synergistic activity of the proteasome inhibitor PS-341 with non-myeloablative 153-Sm-EDTMP skeletally targeted radiotherapy in an orthotopic model of multiple myeloma. Blood 2006;107(10):4063-70.  
10 Mitsiades N, Mitsiades CS, Richardson PG, Poulaki V, Tai YT, Chauhan D, et al. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood 2003;101(6):2377-80.  
11 Sayers TJ, Brooks AD, Koh CY, Ma W, Seki N, Raziuddin A, et al. The proteasome inhibitor PS-341 sensitizes neoplastic cells to TRAIL-mediated apoptosis by reducing levels of c-FLIP. Blood 2003;102(1):303-10.  
12 Yu C, Rahmani M, Conrad D, Subler M, Dent P, Grant S. The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571. Blood 2003;102(10):376574.  
13 O'Connor OA, Smith EA, Toner LE, Teruya-Feldstein J, Frankel S, Rolfe M, et al. The combination of the proteasome inhibitor bortezomib and the bcl-2 antisense molecule oblimersen sensitizes human B-cell lymphomas to cyclophosphamide. Clin Cancer Res. 2006;12(9):2902-11.  
14 David E, Sun SY, Waller EK, Chen J, Khuri FR, Lonial S. The combination of the farnesyl transferase inhibitor lonafarnib and the proteasome inhibitor bortezomib induces synergistic apoptosis in human myeloma cells that is associated with down-regulation of p-AKT. Blood 2005;106(13):4322-9.  
15 McConkey DJ, Pettaway C, Elliott P, Adam J, Papandreou C, Herrmann JL, et al. The proteasome as a new drug target in metastatic prostate cancer. In: 7th Annual Genitourinary Oncology Conference; 1999 February 1999; Houston, TX.  
16 Hideshima T, Richardson P, Chauhan D, Palombella VJ, Elliott PJ, Adams J, et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 2001;61(7):3071-6.  
17 Obeng EA, Carlson LM, Gutman DM, Harrington WJ Jr, Lee KP, Boise LH.  
Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood 2006;107(12):4907-16.  
18 Ling YH, Liebes L, Ng B, Buckley M, Elliott PJ, Adams J, et al. PS-341, a novel proteasome inhibitor, induces Bcl-2 phosphorylation and cleavage in association with G2- M phase 19 Yang Y, Ikezoe T, Saito T, Kobayashi M, Koeffler HP, Taguchi H. Proteasome inhibitor PS-341 induces growth arrest and apoptosis of non-small cell lung cancer cells via the JNK/c-Jun/AP-1 signaling. Cancer Sci 2004;95(2):176-80.  
20 Kaluz S, Kaluzova M, Stanbridge EJ. Proteasomal inhibition attenuates transcriptional activity of hypoxia-inducible factor 1 (HIF-1) via specific effect on the HIF-1alpha Cterminal activation domain. Mol Cell Biol 2006;26(15):5895-907.  
21 An WG, Hwang SG, Trepel JB, Blagosklonny MV. Protease inhibitor-induced apoptosis: accumulation of wt p53, p21WAF1/CIP1, and induction of apoptosis are independent markers of proteasome inhibition. Leukemia 2000;14(7):1276-83.  
22 Roccaro AM, Hideshima T, Raje N, Kumar S, Ishitsuka K, Yasui H, et al. Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells. Cancer Res 2006;66(1):184-91.  
23 Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Fanourakis G, Gu X, et al.  
Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci U S A 2002;99(22):14374-9.  
24 Lightcap ES, McCormack TA, Pien CS, Chau V, Adams J, Elliott PJ. Proteasome inhibition measurements: clinical application. Clin Chem 2000;46(5):673-83.  
25 Orlowski RZ, Stinchcombe TE, Mitchell BS, Shea TC, Baldwin AS, Stahl S, et al.  
Phase I Trial of the Proteasome Inhibitor PS-341 in Patients with Refractory Hematologic Malignancies. J Clin Oncol 2002;20(22):4420-7.  
26 Orlowski RZ, Stinchcombe TE, Mitchell BS, Shea TC, Baldwin AS, Stahl S, et al.  
Phase I Trial of the Proteasome Inhibitor PS-341 in Patients with Refractory Hematologic Malignancies. J Clin Oncol 2002;20(22):4420-7.  
27 Aghajanian C, Soignet S, Dizon DS, Pien CS, Adams J, Elliott PJ, et al. A Phase I Trial of the Novel Proteasome Inhibitor PS341 in Advanced Solid Tumor Malignancies. Clin Cancer Res 2002;8(8):2505-11.  
28 Papandreou CN, Daliani DD, Nix D, Yang H, Madden T, Wang X, et al. Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J Clin Oncol 2004;22(11):210821.  
291 Dimopoulos MA, Anagnostopoulos A, Kyrtsonis MC, Castritis E, Bitsaktsis A,
Pangalis GA. Treatment of relapsed or refractory Waldenström's macroglobulinemia with bortezomib. Haematologic. 2005;90(12):1655-8.  
30 Jagannath S, Barlogie B, Berenson J, Siegel D, Irwin D, Richardson PG, et al. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol 2004;127(2):165-72.  
31 Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, et al. A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma. N Engl J Med 2003;348(26):2609-17.  
32 Bladé J, Samson D, Reece D, Apperley J, Bjorkstrand B, Gahrton G, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 1998;102(5):1115-23.  
33 Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, et al.  
Bortezomib or High-Dose Dexamethasone for Relapsed Multiple Myeloma. N Engl J Med 2005;352(24):2487-98.  
34 Richardson P, Sonneveld P, Schuster M, Irwin D, Stadtmauer E, Facon T, et al.  
Bortezomib Continues Demonstrates Superior Efficacy Compared with High-Dose Dexamethasone in Relapsed Multiple Myeloma: Updated Results of the APEX Trail. Blood 2005;106(11):Abstract 2547.  
35 Fisher R, Bernstein S, Kahl B, Djulbegovic B, Robertson M, de Vos S, et al.  
Multicenter Phase II Study of Bortezomib in Patients With Relapsed or Refractory Mantle Cell Lymphoma. J Clin Oncol 2006;24(30):4867-74.  
36Goy A, Bernstein S, Kahl B, Djulbegovic B, Robertson M, Vos S, et al. Durable Responses with Bortezomib in Patients with Relapsed or Refractory mantle Cell Lymphoma: Updated Time-to-Event Analyses of the Multicenter PINNACLE Study. Blood 2007;110:Abstract 125.  
37 San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008;359(9):906-17.  
38 San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008;359(9):906-17.  
VELCADE (bortezomib) for Injection UCLA Neuro-Oncology Program 8 APPENDICES
8.1 Study Flow Chart UCLA/Millenium Phase II Clinical Study Combining Bortezomib with RT/TMZ  
  
Enrollment
ELIGIBILITY
- Newly-diagnosed glioblastoma
- 2-6 wks from surgery - Other eligibility criteria (Section 5.0)
1Study Regimen:  Bortezomib is given subcutaneously at 1.3 mg/ m² on days 1, 4, 8, 11, 29, 32, 36, and 39 during radiation as early as 14 days after surgery.  Temozolomide is given daily (75mg/m²) during radiation, followed by 5 days out of 28 for 24 additional cycles.  The dose is 150-200 m2 on those days.  Bortezomib at 1.3 mg/m² is given on days 1, 4, 8, and 11 of each subsequent 28 day cycle.  Both bortezomib and temozolomide will continue until progression or up to 24 cycles.  
2 PE/L - physical examination on day 28 of every cycle and at study discontinuation.  Laboratory blood testings weekly during radiation and every cycle thereafter.  
3MRI - at baseline screening within 21 days of day 1; then at day 56; then every 2 cycles (56 days +/- 3 days)
8.2 Karnofsky Performance Status Scale (The following table presents the
untitled h1
karnofsky performance status scale1) neurological

| 100   | Normal, no complaints, no evidence of disease                                |
|-------|------------------------------------------------------------------------------|
| 90    | Able to carry on normal activity                                             |
| 80    | Normal activity with effort; some signs or symptoms of disease               |
| 70    | Cares for self; unable to carry on normal activity or to do active work      |
| 60    | Requires occasional assistance but is able to care for most of his/her needs |
| 50    | Requires considerable assistance and frequent medical care                   |
| 40    | Disabled; requires special care and assistance                               |
| 30    | Severely disabled; hospitalization indicated. Death not imminent             |
| 20    | Very sick; hospitalization necessary; active support treatment necessary     |
| 10    | Moribund; fatal processes progressing rapidly                                |  
DESCRIPTION
0 No neurologic symptoms; fully active at home/work without assistance 1 Minor neurologic symptoms; fully active at home/work without assistance 2 Moderate neurologic symptoms; fully active at home/work but requires assistance 3 Moderate neurologic symptoms; less than fully active at home/work and requires assistance 4 Severe neurologic symptoms; totally inactive requiring complete assistance at home or institution; unable to work
untitled h1
mental status - circle one

0 Normal function 1 Minor mental confusion 2 Gross confusion but awake 9 Unknown  
1 Mor V, Laliberte L, Morris JN, Wiemann M. The Karnofsky Performance Status Scale:
an examination of its reliability and validity in a research setting. *Cancer* 1984; 53:20022007.
untitled h1
8.3 body surface area and

Body surface area (BSA) should be calculated using the DuBois (preferable) or the Mosteller formula. Creatinine clearance (CrCl) can be calculated using the Cockroft-Gault equation as follows: CrCl (ml/min) = (140-age) (actual wt in kg) 72 x serum creatinine (mg/dl) For females use 85% of calculated CrCl value. Note: In markedly obese patients, the Cockroft-Gault formula will tend to overestimate the creatinine clearance. (Adipose tissue tends to contribute little creatinine requiring renal clearance.)
untitled h1
8.4 new york heart association

The following table presents the NYHA classification of cardiac disease:  
| Class   | Functional Capacity                                                                                                                                                                                                                                           | Objective Assessment                                              |
|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|
| I       | Patients with cardiac disease but without resulting limitations of  physical activity. Ordinary physical activity does not cause undue  fatigue, palpitation, dyspnea, or anginal pain.                                                                       | No objective evidence  of cardiovascular  disease.                |
| II      | Patients with cardiac disease resulting in slight limitation of physical  activity. They are comfortable at rest. Ordinary physical activity  results in fatigue, palpitation, dyspnea, or anginal pain.                                                      | Objective evidence of  minimal  cardiovascular disease.           |
| III     | Patients with cardiac disease resulting in marked limitation of  physical activity. They are comfortable at rest. Less than ordinary  activity causes fatigue, palpitation, dyspnea, or anginal pain.                                                         | Objective evidence of  moderately severe  cardiovascular disease. |
| IV      | Patients with cardiac disease resulting in inability to carry on any  physical activity without discomfort. Symptoms of heart failure or  the anginal syndrome may be present even at rest. If any physical  activity is undertaken, discomfort is increased. | Objective evidence of  severe cardiovascular  disease.            |  
Source: The Criteria Committee of New York Heart Association. Nomenclature and Criteria for Diagnosis of Diseases of the Heart and Great Vessels. 9th Ed. Boston, MA: Little, Brown & Co; 1994:253-256.
untitled h1
8.5 declaration of helsinki world

Ethical Principles for Medical Research Involving Human Subjects Adopted by the 18th WMA General Assembly Helsinki, Finland, June 1964 and amended by the 29th WMA General Assembly, Tokyo, Japan, October 1975 35th WMA General Assembly, Venice, Italy, October 1983 41st WMA General Assembly, Hong Kong, September 1989 48th WMA General Assembly, Somerset West, Republic of South Africa, October 1996 and the 52nd WMA General Assembly, Edinburgh, Scotland, October 2000
untitled h1
a. introduction

1. The World Medical Association has developed the Declaration of Helsinki as a statement of ethical principles to provide guidance to physicians and other participants in medical research involving human subjects. Medical research involving human subjects includes research on identifiable human material or identifiable data.  
2. It is the duty of the physician to promote and safeguard the health of the people. The physician's knowledge and conscience are dedicated to the fulfillment of this duty.  
3. The Declaration of Geneva of the World Medical Association binds the physician with the words, "The health of my patient will be my first consideration," and the International Code of Medical Ethics declares that, "A physician shall act only in the patient's interest when providing medical care which might have the effect of weakening the physical and mental condition of the patient."
4. Medical progress is based on research which ultimately must rest in part on experimentation involving human subjects.  
5. In medical research on human subjects, considerations related to the well-being of the human subject should take precedence over the interests of science and society.  
6. The primary purpose of medical research involving human subjects is to improve prophylactic, diagnostic and therapeutic procedures and the understanding of the aetiology and pathogenesis of disease. Even the best proven prophylactic, diagnostic, and therapeutic methods must continuously be challenged through research for their effectiveness, efficiency, accessibility and quality.  
7. In current medical practice and in medical research, most prophylactic, diagnostic and therapeutic procedures involve risks and burdens.  
8. Medical research is subject to ethical standards that promote respect for all human beings and protect their health and rights. Some research populations are vulnerable and need special protection. The particular needs of the economically and medically disadvantaged must be recognized. Special attention is also required for those who cannot give or refuse consent for themselves, for those who may be subject to giving consent under duress, for those who will not benefit personally from the research and for those for whom the research is combined with care.
9. Research Investigators should be aware of the ethical, legal and regulatory requirements for research on human subjects in their own countries as well as applicable international requirements. No national ethical, legal or regulatory requirement should be allowed to reduce or eliminate any of the protections for human subjects set forth in this Declaration.
untitled h1
b. basic principles for all

1. It is the duty of the physician in medical research to protect the life, health, privacy, and dignity of the human subject.  
2. Medical research involving human subjects must conform to generally accepted scientific principles, be based on a thorough knowledge of the scientific literature, other relevant sources of information, and on adequate laboratory and, where appropriate, animal experimentation.  
3. Appropriate caution must be exercised in the conduct of research which may affect the environment, and the welfare of animals used for research must be respected.  
4. The design and performance of each experimental procedure involving human subjects should be clearly formulated in an experimental protocol. This protocol should be submitted for consideration, comment, guidance, and where appropriate, approval to a specially appointed ethical review committee, which must be independent of the investigator, the sponsor or any other kind of undue influence. This independent committee should be in conformity with the laws and regulations of the country in which the research experiment is performed. The committee has the right to monitor ongoing trials. The researcher has the obligation to provide monitoring information to the committee, especially any serious adverse events. The researcher should also submit to the committee, for review, information regarding funding, sponsors, institutional affiliations, other potential conflicts of interest and incentives for subjects.  
5. The research protocol should always contain a statement of the ethical considerations involved and should indicate that there is compliance with the principles enunciated in this Declaration.  
6. Medical research involving human subjects should be conducted only by scientifically qualified persons and under the supervision of a clinically competent medical person. The responsibility for the human subject must always rest with a medically qualified person and never rest on the subject of the research, even though the subject has given consent.  
7. Every medical research project involving human subjects should be preceded by careful assessment of predictable risks and burdens in comparison with foreseeable benefits to the subject or to others. This does not preclude the participation of healthy volunteers in medical research. The design of all studies should be publicly available.  
8. Physicians should abstain from engaging in research projects involving human subjects unless they are confident that the risks involved have been adequately assessed and can be satisfactorily managed. Physicians should cease any investigation if the risks are found to outweigh the potential benefits or if there is conclusive proof of positive and beneficial results.  
9. Medical research involving human subjects should only be conducted if the importance of the objective outweighs the inherent risks and burdens to the subject. This is especially important when the human subjects are healthy volunteers.
10. Medical research is only justified if there is a reasonable likelihood that the populations in which the research is carried out stand to benefit from the results of the research.  
11. The subjects must be volunteers and informed participants in the research project.
12. The right of research subjects to safeguard their integrity must always be respected.  
Every precaution should be taken to respect the privacy of the subject, the confidentiality of the patient's information and to minimize the impact of the study on the subject's physical and mental integrity and on the personality of the subject.  
13. In any research on human beings, each potential subject must be adequately informed of the aims, methods, sources of funding, any possible conflicts of interest, institutional affiliations of the researcher, the anticipated benefits and potential risks of the study and the discomfort it may entail. The subject should be informed of the right to abstain from participation in the study or to withdraw consent to participate at any time without reprisal. After ensuring that the subject has understood the information, the physician should then obtain the subject's freely-given informed consent, preferably in writing. If the consent cannot be obtained in writing, the non-written consent must be formally documented and witnessed.  
14. When obtaining informed consent for the research project the physician should be particularly cautious if the subject is in a dependent relationship with the physician or may consent under duress. In that case the informed consent should be obtained by a well-informed physician who is not engaged in the investigation and who is completely independent of this relationship.  
15. For a research subject who is legally incompetent, physically or mentally incapable of giving consent or is a legally incompetent minor, the investigator must obtain informed consent from the legally authorized representative in accordance with applicable law. These groups should not be included in research unless the research is necessary to promote the health of the population represented and this research cannot instead be performed on legally competent persons.  
16. When a subject deemed legally incompetent, such as a minor child, is able to give assent to decisions about participation in research, the investigator must obtain that assent in addition to the consent of the legally authorized representative.  
17. Research on individuals from whom it is not possible to obtain consent, including proxy or advance consent, should be done only if the physical/mental condition that prevents obtaining informed consent is a necessary characteristic of the research population. The specific reasons for involving research subjects with a condition that renders them unable to give informed consent should be stated in the experimental protocol for consideration and approval of the review committee. The protocol should state that consent to remain in the research should be obtained as soon as possible from the individual or a legally authorized surrogate.
18. Both authors and publishers have ethical obligations. In publication of the results of research, the investigators are obliged to preserve the accuracy of the results. Negative as well as positive results should be published or otherwise publicly available. Sources of funding, institutional affiliations and any possible conflicts of interest should be declared in the publication. Reports of experimentation not in accordance with the principles laid down in this Declaration should not be accepted for publication.
untitled h1
c. additional principles for medical

1. The physician may combine medical research with medical care, only to the extent that the research is justified by its potential prophylactic, diagnostic or therapeutic value. When medical research is combined with medical care, additional standards apply to protect the patients who are research subjects.  
2. The benefits, risks, burdens and effectiveness of a new method should be tested against
those of the best current prophylactic, diagnostic, and therapeutic methods. This does not exclude the use of placebo, or no treatment, in studies where no proven prophylactic, diagnostic or therapeutic method exists.  
3. At the conclusion of the study, every patient entered into the study should be assured of access to the best proven prophylactic, diagnostic and therapeutic methods identified by the study.  
4. The physician should fully inform the patient which aspects of the care are related to the research. The refusal of a patient to participate in a study must never interfere with the patient-physician relationship.  
5. In the treatment of a patient, where proven prophylactic, diagnostic and therapeutic methods do not exist or have been ineffective, the physician, with informed consent from the patient, must be free to use unproven or new prophylactic, diagnostic and therapeutic measures, if in the physician's judgement it offers hope of saving life, re-establishing health or alleviating suffering. Where possible, these measures should be made the object of research, designed to evaluate their safety and efficacy. In all cases, new information should be recorded and, where appropriate, published. The other relevant guidelines of this Declaration should be followed.
8.6 **Common Terminology Criteria for Adverse Events Version 3.0**
http://ctep.cancer.gov/reporting/ctc.html
untitled h1
8.7 rtog/eortc late radiation morbidity

| Grade                                   |                           |                                                                                                                  |                                                                                                                           |                                                                                                                                                               |                                                                                     |
|-----------------------------------------|---------------------------|------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|
| Toxicity                                | 0                         | 1                                                                                                                | 2                                                                                                                         | 3                                                                                                                                                             | 4                                                                                   |
| BladderLate RT  Morbidity  Scoring                                         | No change  from  baseline | Slight epithelial  atrophy/minor  telangiectasia  (microscopic  hematuria)                                       | Moderate  frequency /  generalized  telangiectasia /  intermittent  macroscopic  hematuria                                | Severe frequency  and  dysuria/severe  generalized  telangiectasia  (often with  petechiae);  frequent  hematuria;  reduction in  bladder capacity  (<150 cc) | Necrosis/c ontracted  bladder  (capacity  <100 cc) /  severe  hemorrha gic cystitis |
| Bone- Late  RT  Morbidity  Scoring      | No change  from  baseline | Asymptomatic;  no growth  retardation;  reduced bone  density                                                    | Moderate pain or  tenderness; growth  retardation;  irregular bone  sclerosis                                             | Severe pain or  tenderness;  complete arrest  of bone growth;  dense bone  sclerosis                                                                          | Necrosis/ spontaneo us fracture                                                     |
| Brain- Late  RT  Morbidity  Scoring     | No change  from  baseline | Mild headache;                                                                                                   | Moderate                                                                                                                  |                                                                                                                                                               |                                                                                     |
| slight lethargy                         | headache; great  lethargy | Severe  headaches;  severe CNS  dysfunction  (partial loss of  power or  dyskinesia)                             | Seizures  or  paralysis;  coma                                                                                            |                                                                                                                                                               |                                                                                     |
| Esophagus - Late RT  Morbidity  Scoring | No change  from  baseline | Mild fibrosis;  slight difficulty in  swallowing  solids; no pain on  swallowing                                 | Unable to take solid  food normally;  swallowing semisolid food; dilatation  may be indicated                                                                                                                           | Severe fibrosis;  able to swallow  only liquids; may  have pain on  swallowing;  dilation required                                                            | Necrosis /  perforation ; fistula                                                   |
| Heart- Late  RT  Morbidity  Scoring     | No change  from  baseline | Asymptomatic or  mild symptoms;  transient T wave  inversion and ST  changes; sinus  tachycardia >110  (at rest) | Moderate angina  on effort; mild  pericarditis; normal  heart size;  persistent abnormal  T wave and ST  changes; low QRS | Severe angina;  pericardial  effusion;  constrictive  pericarditis;  moderate heart  failure; cardiac  enlargement;  EKG  abnormalities                       | Tamponad e / severe  heart  failure/sev ere  constrictiv e  pericarditi s           |
| Joint- Late  RT  Morbidity  Scoring     | No change  from  baseline | Mild joint  stiffness; slight  limitation of  movement                                                           | Moderate stiffness;  intermittent or  moderate joint pain;  moderate limitation  of movement                              | Severe joint  stiffness; pain  with severe  limitation of  movement                                                                                           | Necrosis /  complete  fixation                                                      |
| KidneyLate RT                                         | No change                 | Transient                                                                                                        | Persistent                                                                                                                | Severe                                                                                                                                                        | Malignant                                                                           |
| from                                    | albuminuria; no           | moderate                                                                                                         | albuminuria;                                                                                                              | hypertensi                                                                                                                                                    |                                                                                     |
| CONFIDENTIAL                            | Page 78 of 86             | Amendment 7 version dated February 11, 2014                                                                      |                                                                                                                           |                                                                                                                                                               |                                                                                     |  
| Grade                               |                                                                                                            |                                                                                                                                                     |                                                                                                                                             |                                                                                                             |          |
|-------------------------------------|------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------|----------|
| Toxicity                            | 0                                                                                                          | 1                                                                                                                                                   | 2                                                                                                                                           | 3                                                                                                           | 4        |
| Morbidity                           | baseline                                                                                                   | hypertension;                                                                                                                                       |                                                                                                                                             |                                                                                                             |          |
| Scoring                             | mild impairment  of renal function;  urea 25-35 mg%;  creatinine 1.5- 2.0 mg%;  creatinine  clearance >75% | albuminuria (2+);  mild hypertension;  no related anemia;  moderate  impairment of renal  function; urea >36– 60 mg%; creatinine  clearance >50-74% | severe  hypertension;  persistent  anemia  (<10 g%); severe  renal failure; urea  >60 mg%;  creatinine >4  mg%; creatinine  clearance  <50% | on; uremic  coma /  urea  >100%                                                                             |          |
| LarynxLate RT  Morbidity  Scoring                                     | No change  from  baseline                                                                                  | Hoarseness;  slight arytenoid  edema                                                                                                                | Moderate arytenoid                                                                                                                          | Severe edema;                                                                                               | Necrosis |
| edema; chondritis                   | severe chondritis                                                                                          |                                                                                                                                                     |                                                                                                                                             |                                                                                                             |          |
| Liver- Late  RT  Morbidity  Scoring | No change  from  baseline                                                                                  | Mild lassitude;  nausea;  dyspepsia;  slightly abnormal  liver function                                                                             | Moderate  symptoms; some  abnormal liver  function tests;  serum albumin  normal                                                            | Disabling hepatic  insufficiency; liver  function tests  grossly  abnormal; low  albumin; edema  or ascites | Necrosis /  hepatic  coma or  encephalopa thy          |  
| UCLA Neuro-Oncology Program                    | Grade                                                                          |                                                                                                 |                                                                                                                      |                                                                                                   |                                  |
|------------------------------------------------|--------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------|----------------------------------|
| Toxicity                                       | 0                                                                              | 1                                                                                               | 2                                                                                                                    | 3                                                                                                 | 4                                |
| Lung- Late  RT  Morbidity  Scoring             | Severe  respiratory  insufficien cy /  continuou s O2 /  assisted  ventilation |                                                                                                 |                                                                                                                      |                                                                                                   |                                  |
| Mucous  membrane - Late RT  Morbidity  Scoring | No change  from  baseline                                                      | Asymptomatic or  mild symptoms  (dry cough);  slight  radiographic  appearances                 | Moderate  symptomatic  fibrosis or  pneumonitis  (severe cough); low  grade fever; patchy  radiographic  appearances | Severe  symptomatic  fibrosis or  pneumonitis;  dense  radiographic  changes                      |                                  |
| No change  from  baseline                      | Slight atrophy                                                                 | Moderate atrophy                                                                                |                                                                                                                      |                                                                                                   |                                  |
| and dryness                                    | and telangiectasia;  little mucus                                              | Marked atrophy  with complete  dryness; severe  telangiectasia                                  | Ulceration                                                                                                           |                                                                                                   |                                  |
| Salivary  glandsLate RT  Morbidity  Scoring                                                | No change  from  baseline                                                      | Slight dryness of  mouth; good  response on  stimulation                                        | Moderate dryness  of mouth; poor  response on  stimulation                                                           | Complete  dryness of  mouth; no  response on  stimulation                                         | Fibrosis                         |
| Skin- Late  RT  Morbidity  Scoring             | No change  from  baseline                                                      | Slight atrophy;  pigmentation  change; some  hair loss                                          | Patchy atrophy;  moderate  telangiectasia; total  hair loss                                                          | Marked atrophy;  gross  telangiectasia                                                            | Ulceration                       |
| Small/Larg e intestineLate RT  Morbidity  Scoring                                                | No change  from  baseline                                                      | Mild diarrhea;  mild cramping;  bowel movement  5 x daily slight  rectal discharge  or bleeding | Moderate diarrhea  and colic; bowel  movement >5 x  daily; excessive  rectal mucus or  intermittent  bleeding        | Obstruction or  bleeding,  requiring surgery                                                      | Necrosis /  perforation  fistula |
| Spinal  cordLate RT  Morbidity  Scoring                                                | No change  from  baseline                                                      | Mild Lhermitte's                                                                                | Severe Lhermitte's                                                                                                   | Objective                                                                                         |                                  |
| syndrome                                       | syndrome                                                                       | neurological  findings at or  below cord level  treatment                                       | Mono-,  para-,  quadripleg ia                                                                                        |                                                                                                   |                                  |
| Subcutane ous tissueLate RT  Morbidity  Scoring                                                | No change  from  baseline                                                      | Slight induration  (fibrosis) and loss  of subcutaneous  fat                                    | Moderate fibrosis  but asymptomatic;  slight field  contracture; <10%  linear reduction                              | Severe induration  and loss of  subcutaneous  tissue; field  contracture  >10% linear measurement | Necrosis                         |
| Eye- Late  RT  Morbidity  Scoring              | No change  from  baseline                                                      | Asymptomatic  cataract; minor  corneal  ulceration or  keratitis                                | Symptomatic  cataract; moderate  corneal ulceration;  minor retinopathy  or glaucoma                                 | Severe keratitis;  severe  retinopathy or  detachment;  severe glaucoma                           | Panophth al-mitis;  blindness    |
| RadiationOther  (Specify,  ________)                                                | None                                                                           | Mild                                                                                            | Moderate                                                                                                             | Severe                                                                                            | Lifethreatenin g or  disabling                                  |
untitled h1
8.8 fact/gog-neurotoxicity questionnaire version 4.0

By circling one (1) number per line, please indicate how true each statement has been for you during the past 7 days.  
| Not                                                                                 | A little   | Somewhat     | Quite   | Very   |    |
|-------------------------------------------------------------------------------------|------------|-----|---------|--------|----|
| ADDITIONAL CONCERNS                                                                 | at all     | bit | a bit   | much   |    |
| I have numbness or tingling in my hands………                                          | 0          | 1   | 2       | 3      | 4  |
| I have numbness or tingling in my feet…………                                          | 0          | 1   | 2       | 3      | 4  |
| I feel discomfort in my hands………………….                                               | 0          | 1   | 2       | 3      | 4  |
| I feel discomfort in my feet……………………                                                | 0          | 1   | 2       | 3      | 4  |
| I have joint pain or muscle cramps……………                                             | 0          | 1   | 2       | 3      | 4  |
| I feel weak all over……………………………                                                     | 0          | 1   | 2       | 3      | 4  |
| I have trouble hearing…………………………                                                    | 0          | 1   | 2       | 3      | 4  |
| I get a ringing or buzzing in my ears…………                                           | 0          | 1   | 2       | 3      | 4  |
| I have trouble buttoning buttons………………                                              | 0          | 1   | 2       | 3      | 4  |
| I have trouble feeling the shape of small objects when they are in my hand……………………… | 0          | 1   | 2       | 3      | 4  |
| I have trouble walking…………………………                                                    | 0          | 1   | 2       | 3      | 4  |
| ________________________________                                                    |            |     |         |        |    |  
8.9 **Sample Collection and Handling Requirements; 20S Proteasome Inhibition**
Assay Not applicable. 8.10 **Sample Collection and Handling Requirements; PK** Not applicable. 8.11 **Sample Collection and Handling Requirements; PGx** Not applicable.
untitled h1
8.12 radiation therapy guidelines

Source of guidelines The information that follows is adapted from current guidelines of the Radiation Therapy Oncology Group (RTOG) for standard radiotherapy for glioblastoma in the clinical trial setting. Much of the text is quoted directly, with permission.  
Dose Definition and Schedule Radiotherapy must begin within 35 days (5 weeks) of surgery. One treatment of 2.0 Gy will be given daily 5 days per week for a total of 60.0 Gy over six weeks. Treatment may be omitted on holidays, resulting in slight extension of the total period of treatment. All portals shall be treated during each treatment session. Treatment with a single beam is not acceptable due to unacceptable tumor dose inhomogeneity.
untitled h1
target dose definition

Dose is specified as the target dose, which shall be the dose to the center of the target volume. For the following portal arrangements the target dose shall be specified as follows:
For two opposed coaxial equally weighted beams: on the central ray at midseparation of beams.  
For an arrangement of 2 or more intersecting beams: at the intersection of the central ray of the beams. For complete rotation or arc therapy: in the plane of rotation at the center of rotation. The technique of using two opposing co-axial unequally weighted fields is not recommended due to unacceptable hot spots and unacceptable dose inhomogeneity. However, if this technique is utilized, the dose shall be specified at the center of the target area. Other or complex treatment arrangements: at the center of the target volume.  
Physical Factors Treatment shall be delivered with megavoltage machines of energy ranging from Cobalt 60 up to and including 10 MV photons. Selection of the appropriate photon energy*(ies)* should be based on optimizing the RT dose distribution within the target volume and minimizing dose to non-target normal tissue. Photon energies > 10 MV should be utilized only in dual energy beam arrangements using at least one beam with energy < 10 MV. Source skin distance for SSD techniques or source axis distance for SAD techniques must be at least 80 cm. Source sizes must be no more than 2 cm in Cobalt 60 machines. For Cobalt 60 machines, secondary collimation is required. Boost with electrons, particles, stereotactic radiosurgery, or implants is not permissible.  
Localization, Simulation, and Immobilization The patient shall be treated in the supine or other appropriate position for the location of the lesion. A head-holding device that is transparent to x-rays must ensure adequate immobilization during therapy and ensure reproducibility. The target volume for both the initial volume and the conedown volume shall be based on the preoperative MRI/CT. The initial target volume shall include the contrast-enhancing lesion and surrounding edema *(if it exists)* demonstrated on MRI/CT plus a 2.0 centimeter margin. If no surrounding edema is present, the initial target volume should include the contrastenhancing lesion plus a 2.5 centimeter margin.  
This initial target volume will be treated to 46.0 Gy in 23 fractions. After 46 Gy the conedown tumor volume should include the contrast enhancing lesion (without edema) on the pre-surgery MRI/CT scan plus a 2.5 centimeter margin.  
Treatment Planning Treatment plans may include opposed lateral fields, a wedge pair of fields, rotation, or multiple field techniques. MRI/CT-guided treatment planning is necessary to assure accuracy in the selection of field arrangements.  
Isodose distributions for the initial target volume and the conedown target volume are required on all patients, including those treated with parallel opposed fields. A composite plan is required showing the respective target volumes. The inhomogeneity across the target volume shall be kept to a minimum.  
The minimum dose to the target volume should be kept within 5% of the dose at the center of the volume. The maximum dose should be no higher than 5% of the dose at the center of the target volume.  
Dose Limitations to Critical Structures The lens and cervical spine must be shielded from the direct beam at all times.  
When possible to do without shielding gross tumor, attempts should be made to limit the dose to the optic chiasm to 60 Gy, the retina of at least one eye (but preferably both)to 50 Gy, and the brain stem to 60 Gy.  
Documentation Requirements A copy of the pretreatment MRI/CT, the treatment prescription form, treatment calculation form, simulation films and representative portal films of each initial field must be available to be provided on request to the principal investigator. At the completion of treatment, the following must also be available on request: daily treatment record, all isodose distributions, simulation and portal films of the reduced fields, and the radiotherapy summary.  
| CYP3A3/4                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | Substrates    |                                             |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------|---------------------------------------------|
| Acetaminophen Aifentanil Alosetron Alprazolam Amiodarone Amitriptyline (minor) Amlodipine Anastrozole Androsterone Antipyrine Astemizole Atorvastatin Benzphetamine Bepridil Bexarotene Bromazepam Bromocriptine Budesonide Bupropion (minor) Buspirone Busutfan Caffeine Cannabinoids Carbamazepine Cevimeline Cerivastatin Digitoxin Diltiazem Disopyramide Docetaxel Dolasetron Donepezil Doxorubicin Doxycycline Dronabinol Enalapril Erythromycin Estradiol Ethinyl estradiol Ethosuximide Etoposide Exemestene Dofetilide (minor)  Felodipine Fentanyl Fexotenadine Finaxteride Fluoxetine Flutamide Glyburide | Chlorpromazine Cimetidine Cisapride Citałopram Clarithromycin Clindamycin Clomipramine Clonazepam Clozapine Cocaine Codeine (demethylation) Cortisol Cortisone Cyclobenzaprine (demethylation) Cyclophosphamide Cyclosporine Dapsone Dehydroepiandrostendione Delavirdine Desmethyldiazepam Dexamethasone Dextromethorphan (minor, N-demethylation)  Diazepam (minor; hydroxylation, Ndemethylation) Nefazodone Nelfinavir Nevirapine Nicardipine Nifedipine Niludipine Nimodipine Nisoldipine Nitrendipine Omeprazole (sulfonation) Ondansetron Oral contraceptives Orphenadrine Paclitaxel Pantoprazole Pimozide Pioglitazone Pravastatin Prednisone Progesterone Proguanil Propafenone Quercetin Quetiapine Quinidine Quinine               |                                             |
| CONFIDENTIAL                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | Page 84 of 86 | Amendment 7 version dated February 11, 2014 |